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Clinical characteristics of dementia 
Dementia is a clinical syndrome characterized by an acquired and persistent im-
pairment in multiple cognitive domains that is severe enough to interfere with 
everyday functioning (DSM IV) (American Psychiatric Association, 1994). In most 
patients, it is chronic, progressive, and irreversible. Subtypes of dementia, like Alz-
heimer´s disease (AD), vascular dementia (VaD), frontotemporal lobar dementia 
(FTLD), Lewy bodies dementia (LBD) and Creutzfeldt-Jakob disease (CJD), can be 
defined by progressive cognitive impairment and clinical signs, as well as by their 
typical pattern of neuropathological changes. Standardized clinical and neuropa-
thological criteria for different subtypes of dementia have been proposed in con-
sensus meetings.  
The following are the clinical features of the most common types of dementia:  
• AD is a progressive disorder characterized by an impairment of recent memory 
and of at least one other cognitive domain, such as language, visuospatial func-
tion or executive function.  
• The clinical characteristics of LBD are dementia associated with any two of the 
following three core features: fluctuating cognition or level of consciousness, 
visual hallucinations, and spontaneous parkinsonian motor signs.  
• Three different subtypes of FTLD have been described: one behavioural variant 
of frontotemporal dementia and two language variants, semantic dementia and 
progressive non-fluent aphasia. These three subtypes overlap clinically with mo-
toneuron disease (FTD-MND), corticobasal degeneration (CBD) and progressive 
supranuclear palsy (PSP) (Neary et al., 1998; Seelaar et al., 2011). CBD is charac-
terized by rigidity with focal cortical signs, such as apraxia and aphasia, and of-
ten by frontal-type dementia. PSP is an atypical parkinsonian disorder associat-
ed with progressive axial rigidity, vertical gaze palsy, dysarthria, dysphagia, and 
often dementia.  
• CJD is typically associated with a rapidly progressive course over a period of 
months from symptom onset to death. CJD patients show global cognitive dete-
rioration, significant psychiatric symptoms and prominent motor symptoms, in-
cluding signs of pyramidal, cerebellar, and extrapyramidal involvement.  
• Vascular dementia (VaD) is the second most frequent cause of dementia after 
AD. These patients most often have a dysexecutive syndrome characterized by 
reduced mental processing speed, decreased working memory, and impairment 
of abstract reasoning (Chui et al., 2007).  
Although in vivo criteria for types of dementia are based on clinical features, data 
on abnormal biomarkers, when available, are important to support the early diag-
nosis. The known biomarkers are based on findings of structural neuroimaging 
studies with magnetic resonance imaging (MRI) and molecular neuroimaging with 
positron emission tomography (PET), as well as cerebrospinal fluid analysis of pro-
teins such as amyloid beta or tau proteins (Dubois et al., 2007). 
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Neuropathological characteristics of dementia 
The definitive diagnosis of dementia types relies on neuropathological examination 
of the brain. Dementia syndromes, and neurodegenerative conditions in general, 
are defined as disorders with progressive loss of neurons showing a distinct ana-
tomical distribution characteristic of the different dementia types. Research has 
identified a spectrum of proteins that are immunohistochemically detectable in the 
central nervous system and can serve as a basis for protein-based disease classifica-
tion. This is the reason why certain dementia types are also described as protein 
misfolding or conformational diseases.  
Types of dementia (or neurodegenerative disorders that may cause dementia), 
are characterized by the accumulation of certain proteins (Chui et al., 2007; Kovacs 
et al., 2010). 
In AD, one of the two key proteins is beta amyloid, which is found in amyloid-
positive deposits distributed both diffusely and as dense-core plaques. The other 
important protein is phosphorylated tau (p-tau), which accumulates within neurons 
in the form of neurofibrillary tangles (Braak & Braak, 1991). These two proteins are 
believed to interact and contribute to cognitive impairment (Desikan et al., 2012).  
Phosphorylated tau is also the main protein that accumulates in some forms of 
FTLD, in CBD and PSP, being found in round tau-positive cytoplasmic inclusions in 
the behavioural variant of FTLD, in astrocytic plaques in CBD and in tufted astro-
cytes in PSP. In some forms of FTLD, however, tau negative and TDP 43-positive 
inclusions are present (Mackenzie et al., 2010). The key protein in LBD is alpha-
synuclein, which is found in neuronal inclusions, while in CJD, it is the prionic pro-
tein (PrP), the disease being characterized by fine and coarse granules, as well as 
plaques, that stain positive for this protein.  
VaD may result from various forms of cerebrovascular injury, including post-
stroke syndromes (O´Brien et al., 2003). The challenge of identifying the pathologi-
cal substrates for VaD is complicated by the heterogeneous nature of cerebrovas-
cular disease and the coexistence of other pathologies, including Alzheimer-type 
lesions. It has been suggested that subcortical ischemic vascular dementia (SIVD), 
which is associated with small-vessel disease, lacunar infarcts, and deep white 
matter changes, is the most important subtype of vascular cognitive impairment 
(Roman et al., 2002; Kalaria et al., 2004). 
Overlap between dementia subtypes 
Thorough analysis of the morphological and biochemical markers of proteins (such 
as tau, beta amyloid, synuclein and TDP 43) enables classification of the vast major-
ity of cases of dementia. On the other hand, there can be considerable overlap in 
the patterns of accumulation of different proteins, and this often leads to a diagno-
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sis of co-occurrence of different subtypes of dementia (Kovacs & Budka, 2010; 
Kovacs et al., 2010). This raises the question as to whether the mere detection of a 
particular aggregated protein means that it is really the substrate for the dementia. 
Several studies comparing clinical and neuropathological diagnoses (Brunnstrom & 
Englund, 2009; Jellinger, 2009) have found a relatively low mean rate of agreement 
for the purely clinical diagnoses, which is mainly attributable to the high degree of 
comorbidity in neuropathological disorders (Jellinger, 2006; Kovacs et al., 2008; 
Richards & Brayne, 2009; Brunnstrom & Englund, 2009). Diagnosing dementia 
types is difficult for clinicians and researchers alike, especially in later stages of the 
disease, when comorbidity is more likely to occur (Richards & Brayne, 2009). This 
implies that the neuropathological diagnosis of “comorbidity of particular types of 
dementia” may in some cases be a suitable diagnosis in itself. Since medical treat-
ment for patients with dementia is only indicated when the clinical diagnosis is 
clearly established, cases of comorbidity might be problematic. Besides, the preva-
lence of cases showing comorbidity is not clear, nor is it clear whether there is a 
particular clinical cognitive pattern that can be attributed to comorbidity, and what 
this clinical pattern could be. The present thesis proposes a new way of approach-
ing dementia diagnosis, from a multidimensional point of view.  
Aim and outline of the thesis 
This thesis considers dementia as a multifactorial disease and examines the correla-
tions between clinical, neuropathological and neuroimaging changes in demented 
patients. The main aim of the research underlying this thesis was to correlate clini-
cal and neuropathological findings in dementia. The specific research questions 
were therefore related to (1) correlations between clinical and neuropathological 
diagnoses and (2) clinical features of the dementia syndrome. 
The questions relating to (1) included “Are dementia types different diseases or 
should a dementia syndrome be understood as part of a spectrum of diseases?” 
and “What is the relationship between current clinical and neuropathological diag-
noses in dementia?” 
The questions relating to (2) included “Are there any clinical features common 
to all types of dementia or can different profiles be defined?” and “Are there dif-
ferences in dementia types regarding the presence of vascular risk factors or asso-
ciated symptoms such as neuropsychiatric symptoms?” 
The research was based on three different databases. The first was that of the 
Maastricht Aging Study (MAAS), carried out at Maastricht University in the Nether-
lands (Jolles et al., 1995), while the second and third were composed of data from 
the Netherlands Brain Bank (NBB) (Amsterdam) and the Brain Bank of Navarre 
(Pamplona, Spain). The present thesis brings together five studies that made use of 
these three data sources.  
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In order to answer the first question, we investigated the rate of agreement 
between clinical and neuropathological diagnoses of dementia, as is reported in 
Chapter 2. Chapter 3 focuses on the relationship between the most prevalent 
pathological changes co-occurring in the same brain, namely Alzheimer disease 
(AD)-related, Lewy body (LB)-related and vascular pathology.  
The second main question, “Are there any clinical features common to all types 
of dementia or can different profiles be defined?”, was addressed by studying cases 
with confirmed neuropathological diagnoses, as is discussed in Chapters 4 and 5. In 
Chapter 4, the role of vascular risk factors in dementia is explored by assessing the 
prevalence of a range of risk factors in cases of dementia with neuropathologically 
confirmed AD, vascular dementia (VaD), or mixed AD plus vascular pathology. 
Chapter 5 then reports on an investigation of the prevalence of neuropsychiatric 
symptoms (NPSs) associated with dementia in cases with neuropathologically con-
firmed AD and VaD.  
Results concerning the MRI markers of early stage AD are presented in Chapter 
6. Previous neuropathological studies have reported the parahippocampal gyrus to 
be the first structure to be affected in AD, but neuroimaging studies have been 
focusing on hippocampal volume as a biomarker for the early stages of AD. We 
assessed the role of changes in the parahippocampal gyrus as a neuroimaging bi-
omarker for early stage AD, by measuring the volume of this structure in healthy 
volunteers as well as in patients with amnestic mild cognitive impairment (aMCI) 
and mild AD. The power of the parahippocampal gyrus volume to discriminate 
healthy participants from individuals with mild AD was compared with results using 
hippocampal volume.  
The overall conclusions of this thesis are presented in the chapter entitled 
“Conclusions”. 
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CHAPTER 2  
Co-occurrence of different pathologies 
in dementia: implications for dementia 
diagnosis  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Carmen Echávarri, Saartje Burgmans, Maria Cristina Caballero, Federico García-
Bragado, Frans R.J. Verhey and Harry B.M. Uylings. Co-occurrence of different 
pathologies in dementia: implications for dementia diagnosis. Journal of 
Alzheimer´s Disease (2012) 30 (4): 909-917.  
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The standard for differentiating between dementia subtypes is currently based on 
neuropathological changes, and follows traditional nosological classifications. How-
ever, the high incidence of comorbid neuropathologies complicates the differentia-
tion between dementia diagnoses in the clinic. The aim of this study was to investi-
gate the grades of agreement between clinical and neuropathological diagnoses in 
neurodegenerative disorders, to compare them with rates found in previous stud-
ies, and to propose implications for dementia diagnostics. 200 patients who donat-
ed their brains to the Brain Bank of Navarre (Pamplona, Spain). All patients had 
been diagnosed with a neurodegenerative disorder during life (clinical diagnosis) 
and post-mortem (neuropathological diagnosis). We studied a sample of patients 
with a short average time interval between the last clinical assessment and death 
(4.6 months). Overall, there was a mean grade of agreement of 44.0% between the 
clinical diagnosis and the pure neuropathological diagnosis (i.e. without co-morbid 
neuropathological disorders). This grade of agreement differed between dementia 
subtypes: e.g. 85 % for prion disease, 49 % for Alzheimer´s disease, and 0 % for 
Lewy body dementia. Our data confirm that co-occurrence of multiple neuropatho-
logical disorders is very common in individuals with dementia, and that the under-
lying neuropathology often differs from the neuropathology implied by the clinical 
diagnosis. These findings support a multidimensional approach to diagnosing de-
mentia, in which dementia syndromes are not categorized into diagnostic subtypes, 
but are seen as syndromes characterized by a combination of various neuropatho-
logical dimensions.  
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Introduction 
Dementia is a syndrome resulting from neuropathological changes in the brain 
(Kovacs et al., 2012; Uylings et al., 2002), and dementia subtypes are currently 
classified according to the pattern of these changes. Whereas the pathological 
diagnoses of neurodegenerative disorders usually follow traditional nosological 
classifications, previous research suggests that the clinicopathological correlation is 
weak. Several studies have compared clinical and neuropathological diagnoses 
(Brunnstrom et al., 2009; Galasko et al., 1994; Gay et al., 2008; Jellinger, 2009; Lim 
et al., 1999; Massoud et al., 1999; Nelson et al., 2012; Sabbagh et al., 2009; Vic-
toroff et al., 1995) showing a relatively low mean rate of agreement for the pure 
diagnoses (see Figure 1). This is mainly due to the high degree of comorbidity of 
neuropathological disorders (Brunnstrom & Englund, 2009; Gay et al., 2008; Vic-
toroff et al., 1995; Jellinger, 2006). Hence, the traditional nosological classification 
approach as the gold standard for differentiating between dementia subtypes has 
been called into question (Richards &, Brayne, 2009).  
Further investigation is necessary for several reasons. First, most previous stud-
ies focused mainly on Alzheimer’s disease (AD) and vascular dementia (VaD) 
(Galasko et al., 1994; Gay et al., 2008; Massoud et al., 1999), and failed to take 
other, less frequent neurodegenerative disorders into account. Second, previous 
studies reported contradictory results regarding the agreement between clinical 
and neuropathological diagnoses (Kovacs et al., 2008). Third, the time interval be-
tween the clinical and neuropathological diagnoses in reported investigations 
tended to be rather long. For instance, Brunnstrom et al. (2009) reported that 35% 
of the patients had not visited a physician within the last 2 years before death 
(Brunnstrom & Englund, 2009). This likely affects the concordance between the 
clinical and neuropathological diagnoses, since neuropathological findings may 
change in the course of the illness. 
The main aim of the present study was to investigate the rates of agreement 
between clinical and neuropathological diagnoses in neurodegenerative disorders, 
to compare them with previous studies, and to propose implications for dementia 
diagnostics. We investigated a more extensive spectrum of neurodegenerative 
disorders, and included 200 patients with a short average interval between the 
clinical and neuropathological diagnoses (an average of 4.6 months).  
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Figure 1. 
Note. Rates of agreement (%) between neuropathological and clinical diagnoses of AD and VaD in dif-
ferent studies. The diagnoses on the x-axes represent the neuropathological diagnoses. 
Materials and Methods 
Sample 
The study included all the 231 participants who donated their brains to the Brain 
Bank of Navarre (Pamplona, Spain) between 2004 and 2011. 31 control partici-
pants, defined as subjects without clinical symptoms and without neuropathologi-
cal relevant findings, were excluded from the study. Finally, the sample consisted of 
200 patients. All of them had been diagnosed with a neurodegenerative disorder 
during life (clinical diagnosis) as well as post-mortem (neuropathological diagnosis). 
The criteria used for the clinical diagnoses were derived from the literature, as 
follows: Alzheimer´s disease (AD) (McKhann et al., 1984), Lewy body dementia 
(LBD) (McKeith et al., 1996), Mixed Dementia (MD; i.e. Mixed AD and VaD) (Roman 
et al., 1993), frontotemporal lobar degeneration (FTLD) (Neary et al., 1998), pro-
gressive supranuclear palsy (PSP) (Litvan et al., 1996), corticobasal degeneration 
(CBD) (Boeve et al., 2003), motor neuron disease (MND) (Cairns et al., 2007), prion 
disease (Budka et al., 1995), Parkinson´s disease (PD) (Samii et al., 2004), vascular 
dementia (VaD) (Roman et al., 1993), Huntington disease (HD) (Vonsattel et al., 
1985) and multisystem atrophy (MSA) (Gilman et al., 2008). The criteria used for 
neuropathological diagnoses were derived from the literature as follows: AD (Braak 
& Braak, 1991), LBD (McKeith et al., 1996), MD (Zekry et al., 2003), FTLD (Cairns et 
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al., 2007), PSP (Dickson et al., 2007), CBD (Dickson et al., 2002), MND (Cairns et al., 
2007), prion disease (Budka et al., 1995), PD (Braak et al., 2003), VaD (Kalaria et al., 
2004), HD (Vonsattel et al., 1985), MSA (Trojanowski et al., 2007) and AGD (Saito et 
al., 2004).  
All clinical diagnoses were established by a multidisciplinary team of neurolo-
gist and geriatricians at the Navarre Hospitals Complex, who were blinded to the 
neuropathological data; diagnoses were based on medical history, medical exami-
nation of the patient, course of symptoms, and computerized tomography (CT) 
and/or magnetic resonance imaging (MRI) scans. A neurologist/geriatrician was 
present at the first clinical interview with the patient, in order to establish the di-
agnoses, and at most of the follow-up visits. Neuropsychological assessment was 
additionally performed in a majority of the patients, but not in all. If the dementia 
diagnosis had been changed during the time the patient was followed, the most 
recent diagnosis was used for the present clinicopathological comparison. Clinical 
information was obtained through detailed interviews with the relatives, except for 
cases in which the clinical diagnoses had been changed; in these cases the patient 
was re-examined. The interviews were performed during routine visits or when 
patients were admitted to the hospital for any reason. Only 3 patients couldn’t be 
examined in a follow-up visit. For these 3 patients clinical diagnosis was made then 
exclusively by interviews with their informants. In our total sample of 200 patients, 
the average time interval between the last clinical assessment and death was 4.6 
(SD 5.7) months. 96% of our patients had their last clinical assessment within 1 year 
before death, and only 1 patient had a time interval of over 2 years. 
Neuropathological diagnoses were established by one neuropathologist of the 
Brain Bank of Navarre. A neuropathological diagnosis of mixed dementia (MD) was 
established when vascular components and Alzheimer-related pathology were both 
considered to be severe enough to contribute to the dementia symptoms. For 
vascular pathology, we used the criteria described by Kalaria et al. (2004) (Kalaria 
et al., 2004): (a) a large infarct or several infarcts (> 50 ml tissue loss) or (b) multiple 
microinfarcts (more than 3 with a minimum diameter of 5 mm) or small vessel 
disease (hyalinization, amyloid angiopathy, lacunar infarcts, and/or perivascular 
changes). According to the Kalaria et al. criteria, cases of MD include Alzheimer 
related pathology at a Braak stage above III (Kalaria et al., 2004).  
All patients in the PD group had cognitive impairment, defined as cognitive dys-
function involving memory and/or other domains, but not dementia, which means 
without evident functional impairment. Demographic data for the patients, by 
neuropathological diagnosis, are presented in Table 1. Written informed consent 
was obtained from all patients or their relatives. The study was approved by the 
local Medical Ethics Committee of the Tissue Brain Bank of Navarre and Navarre 
Hospitals Complex (Navarre Health Service). 
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Table 1. Demographic data by neuropathological diagnosis  
  Age (years) Duration of  
illness (years) 
Last assessment-
death (months) 
Weight  
(grams) 
Sex 
 n Mean (range) Mean (range) Mean (range) Mean (range) % women 
All 200 78.7 (15-100) 6.9 (1-29) 4.6 (1-64) 1080.2 (575-1800) 55 
AD 52 82.1 (56-97) 6.5 (1-14) 2.4 (1-15) 1060.3 (850-1800) 69 
LBD 1  84.0  21.0  24.0  1150.0  0 
MD 31 83.4 (50-100) 5.9 (1-19) 4.5 (1-24) 1116.2 (725-1400) 52 
FTLD 4  69.5 (64-73) 10.5 (3-15) 4.3 (1-37) 882.5 (750-980) 50 
PSP 11  77.5 (63-92) 5.5 (3-10) 1.1 (1-4) 1111.8 (800-1400) 54 
CBD 4  71.2 (56-85) 6.2 (5-7) 16.7 (1-64) 991.2 (840-1200) 25 
MND 5 57.5 (49-73) 2.7 (2-3) 2.6 (1-6) 1290.0 (950-1500) 60 
Prion disease 12 64.0 (43-84) 3.5 (1-5) 1.4 (1-5) 1177.6 (850-1700) 27 
PD 2 78.5 (78-79) 12 (4-20) 3 (1-5) 1212.5 (1150-1275) 50 
VaD 4  72.2 (51-84) 9.7 (4-26) 3.4 (1-9) 967.0 (918-1100) 50 
HD 4  61.7 (36-76) 23.0 (6-29) 2.6 (1-6) 1026.2 (700-1255) 25 
MSA 1  70.0  6.0  2.0  925.0  100 
AGD 4  80.7 (71-85) 5.0 (1-14) 3 (1-5) 1199.2 (1125-1328) 50 
Comorbid diagnoses 56 83.2 (65-97) 7.8 (1-20) 5.9 (1-23) 1053.6 (650-1350) 59 
Other diagnoses  9  59.3 (15-82) 6.5 (1-19) 1.5 (1-4) 1129.3 (575-1390) 44 
Note. AD Alzheimer´s disease, LBD Lewy body dementia, MD mixed dementia, FTLD frontotemporal 
lobar degeneration, PSP progressive supranuclear palsy, CBD corticobasal degeneration, MND motor 
neuron disease, PD Parkinson´s disease, VaD vascular dementia, HD Huntington disease, MSA multisys-
tem atrophy, AGD argyrophilic grain disease. Comorbid diagnoses include brains showing more than one 
neuropathological diagnosis, Other diagnoses include 5 cases with a tumor, 1 case with multiple sclero-
sis (MS), 1 case with both a brain tumor and MS, 1 case with hereditary spastic paraplegia (suspected 
diagnosis of FTLD) and 1 case with ceroidolipofuscinosis. Duration of illness = years from onset of symp-
toms to death; Weight = weight of the whole brain (grams)Histopathological procedure 
 
The histopathological procedures were carried out according to standard practice 
at the Tissue Brain Bank of Navarre. The left cerebral hemisphere was frozen and 
the right hemisphere was paraffin-embedded for microscopic examination. Before 
freezing, all findings of the macroscopic inspection of both hemispheres were care-
fully recorded (atrophy, vascular lesions, etc.). If any suspected pathology was 
found in the left hemisphere, the left hemisphere was also paraffin-embedded for 
microscopic examination. Following fixation in formaldehyde (10%) for approxi-
mately three weeks, the brain was sectioned. The procedure for fixing and section-
ing was that recommended by BrainNet Europe. The macroscopic examination of 
the brains included photographing, weighing, pH measurement, taking cerebrospi-
nal fluid samples (where possible) and macroscopic description. Twenty-four paraf-
fin blocks were prepared, and at least one slice from each paraffin block was 
stained with hematoxylin and eosin (H&E). The immunohistochemical stains used 
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for each protein are described in Table 2. The antibody dilutions were: tau (Mouse 
monoclonal antibody, Novocastra, NCL-Tau-2, clone Tau 2)1:100, β amyloid (Mouse 
monoclonal antibodybody, Novocastra, NCL-B- amyloid, clone 6F-3D 1:200, TDP-43 
(Abnova Corporation mouse monoclonal antibody) 1:1500, PrP (Mouse monoclonal 
antibody, Dako Cytomation, clone 3F4) 1:100, α-synuclein (Liquid mouse monoclo-
nal antibody, Novocastra, NCL-L-ASIN, clone KN51) 1:50, ubiquitin (Lyophlized 
monoclonal antibody, Novocastra, NCL-UBICm, clone FPM1) 1:700, and α- β crystal-
lin (Mouse monoclonal antibody, Novocastra, clone ABCrys-512) 1:100.  
 
Table 2. Immunostains used for the neuropathological diagnoses 
REGIONS α  
synuclein
ß-Amyloid Tau TDP-43 Ubiquitin α-ß 
crystalline 
PrP 
Cingulate gyrus x X      
Motor gyrus  X x     
Insular cortex   x     
Frontal gyrus x X x x X X  
Anterior thalamus  X x     
Medial thalamus        
Posterior thalamus        
Putamen   x     
Globus pallidus   x     
Hippocampus x X x x X   
Frontal cortex  x X x x X X  
Temporal cortex x X x x X   
Parietal cortex x X x    x 
Occipital cortex  X x     
Frontal white matter        
Substantia nigra x X x     
Pons x X x     
Medulla oblongata x X x     
Amygdala x X x   X  
Caudate-accumbens  X x x X   
Olfactory bulb  x X x x X   
Nucleus basalis of Meynert x  x     
Cerebellum (vermis)   X     x 
Cerebellum (dentate nucleus)        
 
 
 22 
Statistical analysis  
The rate of agreement between clinical and neuropathological diagnoses was calcu-
lated by dividing the number of cases with agreement between the clinical and 
neuropathological by the total number of clinically diagnosed cases. With Epi Info 
Statcal program, version 6 (November 1993), we compared these rates of agree-
ment between the diagnostic groups using an exact Fisher test. We performed this 
comparison only for the most frequent clinical diagnoses (AD, LBD, MD, FTLD, 
PSP, and Prion disease), since the n of the other diagnoses was not large enough 
for a reliable statistical comparison. 
Results 
Prevalences of clinical and neuropathological diagnoses 
Table 3 shows the frequencies of the clinical diagnoses. The most frequent clinical 
diagnosis was AD, with 80 cases (40 %), followed by MD with 20 cases (10 %) and 
FTLD with 18 cases (9 %). Table 1 shows the frequencies of the neuropathological 
diagnoses. The most frequent neuropathological diagnosis was AD with 52 cases 
(26 %), followed by MD with 31 cases (16 %), prion disease with 12 cases (6 %), PSP 
with 11 cases (6 %) and FTLD with 4 cases (2 %). Comparing Table 1 and 3, it is no-
table, that the number of cases neuropathologically diagnosed as MD appears to 
be higher than the number of cases clinically diagnosed as MD. This is in contrast to 
the other dementias. In addition, fifty-six patients (28 %) had more than one neu-
ropathological diagnosis (see the supplementary table for a detailed overview of 
the co-occurrence of all neuropathologies). Nine patients had ‘other diagnoses’, 
including 5 with a tumor, 1 with multiple sclerosis (MS), 1 with both a brain tumor 
and MS, 1 with hereditary spastic paraplegia (suspected diagnosis of FTLD) and 1 
with ceroidolipofuscinosis.  
Dividing the sample into two groups according to age, we found differences be-
tween the moderately old (younger than 80 years) and very old (80 years or older) 
patients. Of the 86 patients younger than 80 years, 20 (23 %) had comorbidity, 
compared to 36 (32 %) of the 114 patients older than 80 (difference non-
significant).  
Agreement between clinical and neuropathological diagnoses 
Table 3 and Figure 2 present the agreement between clinical and neuropathological 
diagnoses. With respect to the concordance between the clinical diagnosis and the 
pure neuropathological diagnosis, we found an overall agreement rate of 44 % 
(Table 3). The agreement was largest in patients with the clinical diagnoses prion 
disease (85 %), MND (83.3%) and MD (80%). The agreement was substantially low-
er in patients with the clinical diagnoses LBD (0 %), FTLD (22 %), PD (22 %), VaD (27 
%), and AD (49 %). When we consider the concordance of the clinical diagnosis with 
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both the pure and comorbid neuropathological diagnosis (i.e. two or more neuro-
pathological diagnoses were established, and one of these neuropathological diag-
noses is in agreement with the clinical diagnosis), we found an overall agreement 
rate of 66 %. The agreement was substantially larger particularly in patients with 
the clinical diagnosis MD (100%), MND (100%), AD (90 %) and LBD (54 %), see Table 
3. In contrast, the agreement in FTLD and PD was still low (28 % and 33 % respec-
tively). Misdiagnoses (i.e. the neuropathological diagnosis is not in agreement with 
the clinical diagnosis) were most frequent in FTLD (72 %), PD (67 %), and LBD (46 
%).  
The exact Fisher tests show that AD diagnoses had a significantly higher rate of 
agreement compared to LBD and FTLD; MD diagnoses showed a significantly higher 
rate of agreement compared to LBD and FTLD; and FTLD showed a significantly 
higher rate of agreement compared to PSP and prion disease (see table 3).  
 
 
Figure 2. Neuropathological diagnosis for each clinical diagnosis. 
Note. AD Alzheimer´s disease, LBD Lewy body dementia, MD mixed dementia, FTLD frontotemporal 
lobar degeneration, PSP progressive supranuclear palsy, CBD corticobasal degeneration, MND motor 
neuron disease, PD Parkinson´s disease, VaD vascular dementia, HD Huntington disease, MSA multisys-
tem atrophy, AGD argyrophilic grain disease; misdiagnosis = the neuropathological diagnosis was not in 
agreement with the clinical diagnosis; comorbid diagnosis = two or more neuropathological diagnoses 
were established, and one of these neuropathological diagnoses was in agreement with the clinical 
diagnosis; pure diagnosis = the neuropathological diagnosis was in complete agreement with the clinical 
diagnosis.  
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Table 3. Agreement between clinical and neuropathological diagnoses. 
Clinical diagnosis  Agreement with 
pure diagnosis  
Agreement with  
pure and co-morbid  
diagnosis 
Misdiagnosis 
 N n (%) N (%) n (%) 
All 200 88 (44.0) 132 (66.0) 26 (13.0) 
AD 80 39 (48.7a) 72 (90.01) 8 (10.0) 
LBD 13 0 (0.0) 7 (53.8) 6 (46.2) 
MD 20 16 (80.0b) 20 (100.02) 0 (0.0) 
FTLD 18 4 (22.2c) 5 (27.73) 13 (72.3) 
PSP 15 10 (66.6d) 13 (86.6) 2 (13.4) 
CBD 2 1 (50.0) 1 (50.0) 1 (50.0) 
MND 6 5 (83.3) 6 (100.0) 0 (0.0) 
Prion disease * 13 11 (84.6e) 12 (92.3) 1 (7.7) 
PD 9 2 (22.2) 3 (33.3) 6 (66.7) 
VaD 11 3 (27.2) 10 (90.9) 1 (9.1) 
HD 4 4 (100.0) 4 (100.0) 0 (0.0) 
MSA 1 1 (100.0) 1 (100.0) 0 (0.0) 
Other ** 8 8 (100.0) 8 (100.0) 0 (0.0) 
Note. For abbreviations see the legend to Table 1. Pure: the neuropathological diagnosis was in com-
plete agreement with the clinical diagnosis; co-morbid = two or more neuropathological diagnoses were 
established, and one of these neuropathological diagnoses was in agreement with the clinical diagnosis; 
misdiagnosis = the neuropathological diagnosis was not in agreement with the clinical diagnosis. * Of 
the 13 cases with a clinical diagnosis of prion disease, 9 had Creutzfeldt-Jakob disease and 4 FFI. ** 
Including 5 cases with a tumor, 1 with multiple sclerosis (MS), 1 with both a brain tumor and MS and 1 
with ceroidolipofuscinosis. 
1 AD diagnoses had a significantly higher rate of agreement compared to LBD and FTLD (p = 0.003 and 
0.000 respectively); 2 MD diagnoses showed a significantly higher rate of agreement compared to LBD 
and FTLD (p = 0.001 and 0.000 respectively); 3 FTLD showed a significantly lower rate of agreement 
compared to PSP and prion disease (p = 0.002 and 0.001 respectively) 
a AD diagnoses had a significantly higher rate of agreement compared to LBD and FTLD (p = 0.000 and 
0.000 respectively); b MD diagnoses showed a significantly higher rate of agreement compared to LBD 
and FTLD (p = 0.000 and 0.000 respectively); c FTLD showed a significantly lower rate of agreement 
compared to PSP and prion disease (p = 0.001 and 0.000 respectively); d PSP showed a significantly 
higher rate of agreement compared to LBD (p = 0.001); e Prion disease showed a significantly higher rate 
of agreement compared to LBD (p = 0.000).  
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Supplementary table. Most frequent clinical diagnoses (rows) and neuropathological diagnoses (col-
umns).  
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AD   39 1  14 2 3  2 2 1 2# 4             10     80
LBD    6    1    1 1     1       2 1    13
MD 5   4                     11     20
FTLD 6    1  4  1     1  1 1      1  1    1 18
PSP    1 1              10 1 1  1       15
CBD 1        1                     2 
MND            1   5               6 
Prion 
disease 
                11 1    1        13
PD 1  2 4                  1  1      9 
VaD                   1      7 3    11
HD                           4   4 
MSA                            1  1 
Other                             8 8 
 52 1 2 29 4 3 4 3 4 1 2 6 1 1 5 1 12 2 11 1 1 2 2 1 31 4 4 1 9 200
Note. # 1 of these 2 patients showed motor neuron involvement. AD Alzheimer´s disease, LBD Lewy 
body dementia, MD mixed dementia, FTLD frontotemporal lobar degeneration, PSP progressive supra-
nuclear palsy, CBD corticobasal degeneration, MND motor neuron disease, PD Parkinson´s disease, VaD 
vascular dementia, HD Huntington disease, MSA multisystem atrophy, AGD argyrophilic grain disease.  
Discussion 
Our results confirm that the agreement between clinical and neuropathological 
diagnoses in neurodegenerative disorders is far from optimal. The majority of the 
clinical diagnoses did not fully correspond with the neuropathological diagnoses. 
This was mainly due to the fact that co-occurrence of neuropathological disorders 
was very common, i.e., a large number of patients had multiple neuropathological 
diagnoses at the post-mortem examination. A possible explanation for the high 
frequency of co-morbid depositions in dementia is that certain protein deposits 
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may influence the formation of other deposits (Kovacs et al., 2012). For instance, 
there is evidence that tau and α synuclein can promote each other’s fibrillization 
(Clinton et al., 2010). This is in line with our finding that LB (Lewy body)-related 
pathology frequently co-occurred with AD pathology, and vice versa (see Table 3).  
Compared to previous studies (Kovacs et al., 2012; Brunnstrom & Englund, 2009; 
Galasko et al., 1994; Jellinger, 2006; Echávarri et al., 2011), our agreement rates are 
relatively high. This may be due to the fact that our sample had a relatively short 
average time interval between the last clinical assessment and death. This relative-
ly high concordance compared to other studies is particularly evident with respect 
to AD and VaD (See Figure 1). When we included both the pure and comorbid neu-
ropathological diagnoses in our analysis, our sample had the highest agreement 
rates for AD as well as for VaD, comparing to other studies. When we included only 
the pure diagnosis, our sample had the second highest agreement rates for AD and 
VaD (Fig.1). Our results also show that the co-occurrence of neuropathologies is 
likely to increase with advanced age, as the incidence of comorbidity was higher in 
the patients above the age of 80. This is in line with other results for community-
dwelling older persons and autopsy series (Galasko et al., 1994; Gay et al., 2008; 
Gilman et al., 2008; Echávarri et al., 2011). Note that the mean age of our sample 
was similar to those in the studies that we used to compare our concordance rates 
with.  
In our sample, the agreement between clinical and neuropathological diagno-
ses differed substantially between different neurodegenerative disorders. Patients 
with a clinical diagnosis of LBD, FTLD, PD, VaD and MD had low agreement rates, 
while patients with prion disease, HD, MSA or MND had high agreement rates. 
These data are largely in agreement with previous reports, particularly regarding 
LBD and VaD (Brunnstrom & Englund, 2009; Gay et al., 2008; Massoud et al., 1999), 
supporting the view that both diseases rarely appear as pure pathologies but are 
very likely to be found in association with other pathologies. Another notable find-
ing is the high prevalence of prion disease. Navarre is a region bordering on the 
Basque Country, where the rate of prion disease is the highest in Europe (Zarranz 
et al., 2006). The 4 cases diagnosed in our series with fatal familial insomnia (FFI) 
were members of the same family. They showed a mutation of the prionic protein 
gene D178N (Trojanowski et al., 2007), which has been shown to be more frequent 
in Spain (specifically in Basque Country and Navarre) than in other countries in 
Europe (Iriarte et al., 2007).  
The current results indicate that diagnosing patients with the traditional noso-
logical classification approach is rather artificial, since the underlying neuropathol-
ogy often differs from the neuropathology implied by the dementia subtype. This 
underlines the necessity of a multidimensional approach as advocated by Richard 
and Brayne (Richard & Brayne, 2009); that is, dementia, especially in older patients, 
should not be categorized into isolated subtypes, but should be seen as a diffuse 
clinical syndrome representing the gradual accumulation of multiple pathologies. 
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Therefore, a diagnosis of dementia should not be specified by a dementia subtype, 
but should reflect a spectrum of neuropathological dimensions such as the for-
mation of beta amyloid, phosphorylation of tau, vascular changes and other pa-
thologies. For instance, if a patient is diagnosed with AD in vivo, the likelihood of 
finding AD-related pathology plus a comorbid pathology - such as Lewy bodies and 
vascular pathology - in the neuropathological assessment is higher than the likeli-
hood of only finding pure AD.  
We think that a multidimensional approach will not only increase the accuracy 
of dementia diagnoses, but will also lead to a better understanding of neurodegen-
erative diseases by clinicians, since it stresses that these diseases have a multifac-
torial nature. An important question is what effect a multidimensional approach 
has on the diagnosis of dementia. Instead of being diagnosed with a specific de-
mentia subtype, a patient will then receive a less specific diagnosis of ‘dementia’, 
including a spectrum of symptoms. This diagnosis is closer to the truth and will 
probably lead to fewer misdiagnoses. It also takes into account the uncertainties 
that exist with respect to the role of biomarkers in dementia subtypes. Although 
many biomarkers, such as white matter lesions and amyloid depositions, are now-
adays seen as indicators of specific dementia subtypes, the specificity of these 
pathological changes is still unclear. Note that we do not want to induce an attitude 
in clinicians of being oversimplistic by making a generic dementia diagnosis. In-
stead, we want to encourage clinicians to recognize different neuropathological 
features and the specific contribution of each of them to the dementing process. 
We wish they take into account the large spectrum of neuropathological findings 
and the complexity of neurodegenerative disorders 
A few methodological issues need to be mentioned. First, previous studies of-
ten used FTLD as an umbrella term to represent a spectrum of pathological entities, 
including PSP and CBD. In our study we considered FTLD, PSP, and CBD as separate 
entities, based on the clinical syndromes previously described (Neary et al.,1998; 
Sha et al., 2006). If we had included CBD and PSP in the FTLD group, the clinico-
pathological agreement for FTLD would have been higher. Second, the patients in 
our sample were studied retrospectively and were diagnosed in vivo. Cases of AD, 
LBD, and VaD met criteria for both possible and probable dementia. It is possible 
that the use of criteria for probable diagnosis, excluding possible diagnosis accord-
ing to NINCDS-ADRDA criteria (McKhann et al., 1984), would have resulted in a 
better concordance. Third, the high prevalence of FTLD and prion disease demon-
strates that our sample is not entirely representative of the European population. 
This is mainly caused by the fact that patients with more exotic neuropathologies 
are more likely to become Brain Bank donors, and by the high prevalence of prion 
disease in the region of Navarre and Basque Country (Jicha et al., 2008, Schneider 
et al., 2009).  
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To conclude, we believe that these data support the notion that a multidimen-
sional approach to diagnosing dementia would increase the accuracy of clinical 
diagnoses as well as understanding the complexity of neurodegenerative diseases. 
In addition, these data underline the importance of neuropathological confirmation 
of dementia diagnoses in studies about dementia subtypes. 
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CHAPTER 3  
Associations between Alzheimer 
pathology, Lewy bodies and 
cerebrovascular lesions in demented 
patients 
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Associations between Alzheimer pathology, Lewy bodies and cerebrovascular 
lesions in demented patients. Submitted. 
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In patients with Alzheimer’s disease (AD), the typical AD neuropathological features 
(neurofibrillary tangles and senile plaques) frequently co-occur with other neuropa-
thological findings, particularly cerebrovascular lesions (CVLs) and Lewy bodies 
(LBs). The relationship between the severity of AD pathology and these comorbid 
pathologies is unclear. The present neuropathological study investigated the asso-
ciations between the degree of Alzheimer pathology (i.e., Braak stage), CVLs and 
LBs in demented patients. The study included 101 patients who donated their 
brains to the Brain Bank of Navarre between 2004 and 2011. All patients were 
diagnosed in vivo with dementia, and received a post-mortem neuropathological 
diagnosis of AD. The mean time interval between the last in vivo clinical assess-
ment and death was 4.2 months. Patients with large-vessel disease were excluded. 
With respect to the whole-brain analyses, we found a significant positive relation-
ship between AD Braak stage and CVL severity. As for the regional analyses, we 
only found a significant correlation between AD Braak stage and CVL severity in the 
frontal cortex. No relationship was found between Braak and LB stage. Our study 
supports a positive association between AD pathology and CVLs in demented pa-
tients with AD, suggesting that AD and CVLs may have a common aetiopathogene-
sis. In contrast, we found no evidence to suggest a direct link between AD and LB 
pathology in these patients. 
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Introduction 
Neurofibrillary tangles (NFTs) and senile plaques, including neuritic plaques (NPs), 
are considered to be neuropathological hallmarks of Alzheimer’s disease (AD) 
(Braak & Braak., 1990; Braak et al., 2006; Montine et al., 2012). The severity of AD 
pathology is generally staged according to Braak and Braak criteria, taking into 
account the amount and site of the deposition of NFTs and NPs (Braak & Braak, 
1991). Our data at the Navarre Brain Bank show that most donors who meet the 
clinical criteria for AD have a high Braak and Braak stage, viz. V-VI (Echávarri, 2011). 
It is well-known that other neuropathological features frequently co-exist in AD 
brains. Findings that most frequently co-occur with AD are cerebrovascular lesions 
(CVLs) and Lewy bodies (LB) (Snowdon et al., 1997; de Leeuw et al., 2004; Schnei-
der et al., 2007; Parkkinen et al., 2008; Foster et al., 2010; Nelson et al., 2010). 
Furthermore, AD-related pathology can be found together with tauopathies such as 
corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), or TDP-43 
inclusions (Tomlinson et al., 1970; Jellinger, 2006; Nelson et al., 2007; Kovacs et al., 
2008; Brunnstrom & Englund, 2009; Echávarri et al., 2011). Comorbid neuropatho-
logical processes are thus very common in Alzheimer patients. It is, however, un-
clear whether there is a relationship between the severity of AD and these comor-
bid neuropathological features.  
To date, studies investigating the relationship between CVLs and Braak stage 
have produced inconsistent results. Some research has shown a positive relation-
ship, with higher neuritic Braak stages co-occurring with an increased incidence and 
severity of vascular pathology (Jellinger, 2003; Jellinger, 2008; Jellinger, 2010), 
while other studies have found an inverse relationship (Goulding et al., 1999; 
Jellinger, 2000; Sonnen et al., 2011), with more AD pathology correlating with few-
er CVLs. Contradictory results were also found when studying the relationship be-
tween the severity of AD- and LB-related pathologies. While Oinas et al. (2009) 
(Oinas et al., 2009) found a positive correlation between Braak stage for AD and the 
extent of LB-related pathology (Oinas et al., 2009), other researchers have reported 
the opposite (Selikhova et al., 2009; Compta et al., 2011; Sonnen et al., 2011). All 
the aforementioned studies were performed post-mortem. Regarding the relation-
ship between AD and CVL severity, the contradictory findings may be explained by 
the lack of consensus in defining the severity of CVLs. On the other hand, with re-
spect to the association between AD and LB severity, there is a lack of consensus in 
the classification of the stages of the pathologies, and again this may explain the 
inconsistent results.  
The main aim of the present study was to investigate whether or not there is a 
correlation between the degree of Alzheimer pathology (i.e., Braak stage) and vas-
cular lesions and LBs. We investigated 101 brains of demented individuals who had 
donated their brains to the Brain Bank of Navarre (Pamplona, Spain). The patients 
were diagnosed in vivo with dementia, and post-mortem neuropathological diag-
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noses confirmed AD. The sample consisted of 62 cases with pure AD and 39 cases 
with AD with comorbidity. Comorbidity was defined as a degenerative neuropatho-
logical process (sufficiently severe to warrant a separate diagnosis) other than AD. 
The secondary aim of the study was to add to previous data concerning an im-
portant issue namely the distinction between pure AD and AD with comorbidity. 
These data enabled us to investigate whether the relationship between AD pathol-
ogy and CVLs is modified by a comorbid degenerative neuropathological process. 
We hypothesized that, if the severity of AD-related pathology and CVLs were relat-
ed in patients with AD, the relationship might be mediated by the existence of a 
comorbid degenerative neuropathological process.  
Materials and Methods 
Sample 
This study included 101 patients who donated their brains to the Brain Bank of 
Navarre between 2004 and 2011. They were diagnosed with dementia during life 
(clinical diagnosis) and a neuropathological diagnosis of AD was made at post-
mortem. Specifically, of the 296 donors to the Brain Bank, 113 demented patients 
were found to have AD pathology on post-mortem analysis. Since the present study 
focused on small-vessel disease, twelve patients with large-vessel lesions (territori-
al infarcts or lobar bleedings) were excluded. The 101 subjects studied included 
cases with pure AD and cases with AD plus a comorbid neuropathological process. 
Comorbid diagnoses included degenerative pathologies other than AD. Neuropa-
thological diagnoses of the 101 patients were as follows: 62 pure AD; 33 AD + LB 
dementia (LBD); 2 AD + frontotemporal lobe degeneration (FTLD) with TDP-43-
positive inclusions; 2 AD + PSP; 1 AD + CBD; 1 AD + LB in the amygdala. Patients 
with  LBs only in the amygdala were given the diagnosis of LBD.  
In the last clinical assessment before death, all subjects scored 2 or 3 on the 
Clinical Dementia Rating (CDR) scale, indicating moderate to severe dementia 
(Morris et al., 1993). The mean time interval between this clinical assessment and 
death was 4.2 months. Neuropathological diagnoses were made by the same expe-
rienced neuropathologist of the Brain Bank of Navarre (MCC) according to the 
standard criteria for AD (Braak & Braak, 1991), LBD (McKeith et al., 1996), PSP 
(Dickson et al., 2007), CBD (Dickson et al., 2002), and frontotemporal lobar degen-
eration (FTLD) with TDP-43 positive inclusions (Cairns et al., 2007). The severity of 
small-vessel CVLs (from 0 to 2) was assessed for each case in a semi-quantitative 
way (see Table 1). In the group of pure AD, 17 cases (22.6%) were found to have at 
least one non-strategic lacunar infarct, 15 (24%) one strategic infarct (8 in caudate 
nucleus, 5 in thalamus and 2 in parietal cortex), 28 (45.2%) cortical amyloid angiop-
athy and 36 (58.1%) diffuse white matter changes. In the group of AD with comor-
bidity, 7 cases (17.9%) had at least one non-strategic lacunar infarct, 2 (5.1%) one 
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strategic infarct (both in caudate nucleus), 11 (28.2%) cortical amyloid angiopathy 
and 22 (56.4%) diffuse white matter changes.  
Regional analyses of AD-related tissue were performed, in particular classifying 
the amount of NFTs semi-quantitatively according to the following criteria (lesions 
counted within the microscopic field with a diameter of 0.79 mm2 at x200 magnifi-
cation): NFT: none = 0; 1 = + (sparse); 2 = ++ (moderate, more than 6 NFT per mm2); 
3 = +++ (frequent, more than 20 NFT per mm2)  
An average score (between 0 and 3) was calculated, representing the density of 
NFTs in each region studied (hippocampus, amygdala, temporal and frontal cortex).  
The LBD cases were classified into three types as in Mc Keith et al. (McKeith et 
al., 2005) on the basis of the amount of LB and their distribution across brain re-
gions (i.e., into brainstem, limbic and neocortical types). The Braak and Braak stage 
for AD ranged from III to VI.  
Demographic data for the patients are presented in Table 2. Written informed 
consent was obtained from all patients or their close relatives.  
 
Table 1. Classification of cerebrovascular lesions (CVLs) 
0 No concomitant CVLs 
1 Minimal CVLs: 1-2 small lacunes, mild-moderate cerebral amyloid angiopathy (CAA), 
mild CVLs, mild leukoencephalopathy 
2 Moderate CVLs: >2 lacunes, severe subcortical lacunar state, severe CAA with mod-
erate CVLs, diffuse white matter lesions 
 
Table 2. Demographical data 
 Age (years) 
Mean (SD) 
Gender 
(% female) 
Time from diagnosis 
to death (years) 
Mean (SD) 
Braak stage (AD) 
Mean (SD) 
AD  
(n = 62) 
82.5 (8.0) 65.0 6.5 (3.3) 5.5 (0.7) 
AD + comorbidity  
(n = 39) 
84.0 (7.4) 56.0 8.5 (4.4) 4.5 (1.0) 
P 0.342 0.224 0.014 0.000 
 
The whole-group analyses revealed a significant positive relationship between AD 
Braak stage and CVL severity (r = 0.19, p = 0.048). That is, higher Braak stages were 
associated with more CVLs. The post-hoc analyses, in which we performed separate 
calculations for patients with pure AD and patients with AD plus a comorbid neuro-
pathological process, differences did not reach significance. See Figure 1. When 
LBD stage was included as a covariate in the partial correlation for the whole group 
of AD participants, the relationship was no longer significant (r = 0.18, p = 0.07). 
Figure 2 shows the prevalence of the CVL categories per Braak stage, with the 
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number of subjects for each Braak stage set to 100%. This demonstrates that the 
relative number of patients with vascular lesions (CVL score = 1 or 2) increases with 
higher Braak stages. 
With respect to regional analyses, considering the hippocampus, amygdala, 
temporal cortex and frontal cortex separately, the only significant correlation was 
found (r = 0.21; p = 0.034) between the amount of NFTs and severity of CVLs in the 
frontal cortex and for the two groups together (‘AD pure’ and ‘AD with comorbidi-
ty’).  
No significant association was found between AD Braak stage and LBD stage, 
either in the whole-brain analysis or in the regional analyses.  
 
Figure 1. Cerebrovascular lesion (CVL) severity per Braak stage 
(see Table 1 for the classification of CVLs) 
a) Whole group analysis 
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b) Post-hoc analysis in which we analysed the pure AD group (left) and AD with comorbidity group 
(right) separately 
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Figure 2. Prevalence of the CVL categories per Braak stage.  
In this figure, the number of subjects for each Braak stage was set at 100%. This demonstrates that the relative 
number of patients with vascular lesions (CVL = 1 or 2) increases with higher Braak stages  
a) Whole group analysis 
 
b) Post-hoc analysis in which we analysed the pure AD group (left) and AD with comorbidity group (right) sepa-
rately 
Discussion 
We studied a sample of 101 participants with a diagnosis of dementia during life 
and AD-related pathology in the neuropathological assessment at post-mortem. 
We found that higher Braak and Braak stages are associated with more severe 
vascular lesions, in particular in the frontal cortex. This is in line with the report of 
Jellinger et al. (2008) (Jellinger et al., 2008), who studied a sample of 100 patients 
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with Parkinson´s disease and 20 patients with LBD and AD-related pathology and 
found a positive relationship between CVL severity and AD Braak stage. Previous in 
vivo studies have also shown a positive correlation between AD and CVLs (Kim et 
al., 2001; Yoshita et al., 2006). Our results are, however, not consistent with two 
previous neuropathological studies that found a negative relationship between 
Braak stage and vascular lesions: Goulding et al. in 1999 (Goulding et al., 1999) and 
Jellinger et al. in 2000 (Jellinger et al., 2000). Both studies were based on very small 
samples (25 and 27 cases respectively), and although all cases had predominantly 
AD-type dementia, no other details were provided regarding their diagnoses. This 
could explain the contradictory results. Indeed, when Jellinger et al. studied a much 
larger sample in 2008 (120 cases) all cases showed co-occurrence of AD and LB 
related pathologies, and in this more recent study they found a positive correlation. 
We therefore conclude that, overall, our positive relationship between AD Braak 
stages and CVL severity are in line with the other available evidence. This suggests 
that AD pathology and CVLs have a common aetiopathogenesis in demented pa-
tients. 
In order to investigate whether this relationship between AD pathology and 
CVLs is modified by the presence of a comorbid degenerative neuropathological 
process, we divided our sample into two groups: cases with pure AD and cases with 
AD plus a comorbid neuropathological process (note that these comorbid diagno-
ses included other degenerative conditions, but not vascular dementia). Although 
we did not find any significant associations, this may be due to the small number of 
subjects in each subgroup, and accordingly we are unable to rule out that the posi-
tive association between AD Braak stage and CVLs is mediated by a comorbid de-
generative neuropathological process. In fact, since the results were not significant 
when LBD stage was included as a covariate, we can state that LB pathology is a 
mediating factor in the positive relationship between severity of CVL and AD-
related pathology.  
In the present study, we found no correlation between AD Braak stage and 
Lewy body stage. No prior studies have been performed in samples with compara-
ble characteristics to ours, and research that has been conducted has produced 
contradictory results (Sonnen et al., 2011; Compta et al., 2011). Sonnen et al. (Son-
nen et al., 2011) studied a sample of 336 cognitively normal adults and found an 
inverse relationship, while Compta et al. (Compta et al., 2011) found a positive 
relationship in a sample of 56 participants with a diagnosis of Parkinson´s disease, 
who in most cases had an AD-related tauopathy at a Braak stage of III-IV. We be-
lieve that the lack of homogeneity in the clinical characteristics of the participants 
and the severity of the degenerative pathology may have led to these contradictory 
results. In any case, we underline that the present data do not support the idea of a 
direct relationship between AD pathology and LB in demented patients with AD. 
With regard to the regional analysis, the only significant correlation was found 
in the frontal cortex. We hypothesize that AD-related pathology in the frontal cor-
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tex may lead to disruption of the fronto-subcortical pathway and make it more 
susceptible to vascular damage due to small-vessel disease or demyelination of the 
white matter at the frontal area.  
Finally, we address the limitations of our study. First, the small number of par-
ticipants in each subgroup of AD patients may be responsible for the lack of signifi-
cant results in the post-hoc analyses. Second, most of our patients were at Braak 
stages V or VI. This narrow range of Braak stages may have hampered our ability to 
find robust correlations. Both limitations are not uncommon in post-mortem stud-
ies and are a result of the fact that we studied tissue from deceased patients.  
In conclusion, our study provides new evidence for a link between AD patholo-
gy and CVLs in demented patients with AD, suggesting that AD and CVLs may have 
a common aetiopathogenesis. Our data do not, however, support the theory of a 
direct relationship between AD pathology and LB in these patients.  
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CHAPTER 4 
Vascular risk factors in 
neuropathologically confirmed 
Alzheimer´s disease and vascular 
dementia 
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Previous in vivo studies have reported various vascular conditions to be risk factors 
for dementia. Our main aim was to compare vascular risk factor prevalence in neu-
ropathologically confirmed cases of Alzheimer´s disease (AD), vascular dementia 
(VaD), and mixed AD and VaD (MD). We compare the results with prevalences in 
elderly local Dutch control populations. The target population of this retrospective 
descriptive study comprised 120 brains selected from donations to the Netherlands 
Brain Bank between 1984 and 2010. Forty VaD patients were matched with 40 AD 
and 40 MD patients. Data from several control groups representing the elderly 
Dutch population were also included for comparison. 
 The only differences found were a greater prevalence of history of stroke in VaD 
and MD patients compared to AD patients and controls, and a greater prevalence 
of smoking in AD. We argue that none of the risk factors we examined may be re-
lated to the presence of dementia, except for stroke history in VaD.  
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 Introduction 
Multiple vascular risk factors, such as hypertension, diabetes, history of stroke, 
atrial fibrillation, hypercholesterolaemia and smoking have been recognised to be 
associated with dementia, in particular vascular dementia (VaD) but also Alz-
heimer´s disease (AD) (Cherubini et al., 2007; Henon et al., 2000; Kalaria, 2000; 
Kivipelto et al., 2001; Skoog et al., 1996). Other studies have failed to distinguish a 
particular vascular risk factor pattern associated with subtypes of dementia (AD or 
VaD) (Arvanitakis et al., 2004; Breteler et al., 1994; Luchsinger et al., 2001; 
Luchsinger et al., 2004; Luchsinger et al., 2005; O´Brien et al., 2003; Ott et al., 1998; 
Ott et al., 1999; Pohjasvaara et al., 1998; Kivipelto et al., 2001; Knopman et al., 
2001; Kuller et al., 2005; Reitz et al., 2008; van Vliet et al., 2010). One possible ex-
planation for this might be the lack of consensus about the clinical diagnoses of 
VaD, AD and mixed AD and VaD cases (MD). In fact, previous research has shown 
that clinical diagnoses often have to be revised when neuropathological findings 
become available (Brunnstrom & Englund, 2009; Kovacs et al., 2008; Echávarri et 
al., 2012). In addition, AD-related and vascular pathologies commonly co-occur 
(Parkkinen et al., 2008; Trojanoswki et al., 2003), which complicates the diagnosis 
of dementia subtypes. The main aim of our study was to compare the prevalence of 
vascular risk factors in neuropathologically confirmed AD, VaD and mixed AD and 
VaD (MD). We compared the results with prevalences in several elderly local Dutch 
control populations. To the best of our knowledge, this is the first combined clinico-
neuropathological study on this topic.  
Material and methods 
Cases 
The target population for this retrospective descriptive study comprised 120 brains 
selected from donations to the Netherlands Brain Bank (NBB) between 1984 and 
2010. Necropsy authorization and informed consent were obtained from each 
donor, relative or caregiver. We included all 40 cases diagnosed with VaD during 
this period (1984 to 2010), as well as 40 cases of AD and another 40 cases of MD. 
During the period in which the VaD cases were collected, 660 AD cases were identi-
fied at the NBB. Cases of AD, VaD, and MD were matched where possible for age 
and the Braak stage of AD-related neurofibrillary tangle pathology. The stages, as 
defined in Braak (Braak et al., 2006),  were IV or V for AD cases, III or less for VaD, 
and IV or V for MD. Brains at Braak stage VI were not included, since they were 
older than the other cases. More details of the diagnostic criteria used are present-
ed in the next subsection, Neuropathological assessment. Brains from the NBB with 
a mixture of other neurodegenerative disorders or any other structural lesions 
were also excluded.  
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The NBB donors were recruited from nursing homes. All demographic information 
(age, sex, duration of dementia), clinical data including risk factors (hypertension, 
history of stroke, diabetes, hypercholesterolaemia, atrial fibrillation, smoking) and 
neuropathological data were collected from patient medical records and NBB re-
cords. These data were provided by the patient’s family doctor, the doctor at the 
nursing home, the patient’s neurologist and/or psychiatrist. The patients were 
considered to have had hypertension if they had one of the following: self-report of 
physician-diagnosed hypertension, use of antihypertensive medication, or blood 
pressure ≥ 160/95. They were considered to have had hypercholesterolaemia if 
their recorded total cholesterol ≥ 6.5 mmol/L. History of stroke included transitory 
ischemic attack (TIA) as well as actual stroke.  
As regards hypertension, 67.5% of the patients were reported as having had 
midlife hypertension and 15.5% as having had late-life hypertension, while no dis-
tinction between late-life or mid-life hypertension could be made in 17.5% of the 
patients. Neuropathological diagnoses were reviewed by an experienced neuropa-
thologist (WK), while the medical records were examined by an experienced neu-
rologist (CE).  
Control group data derived from several epidemiological studies involving el-
derly Dutch populations were compared with the data from the sample of dement-
ed cases from the Brain Bank. These subjects from Dutch populations had been 
selected at random. Most of them were living at home, and a few of them in nurs-
ing homes. Data on hypertension were collected from Van Rossum et al. (2000) 
(Rossum et al., 2000), data on atrial fibrillation from Heeringe et al. (2006) (Heer-
inge et al., 2006)), data on history of stroke and diabetes from the Nijmegen Con-
tinuous Morbidity Register (Van de Lisdonk E. Personal communication, 2012), data 
on hypercholesterolaemia from the Measuring the Netherlands study (Verschuuren 
M. Personal communication, 2012), and data on smoking from the Dutch Continu-
ous Survey of Smoking by STIVORO (2010) (Zeegers T. Personal communication, 
2012). All but one of the control groups were chosen so as to comprise individuals 
aged between 75 and 84 years, in order to ensure that they were as similar as pos-
sible to the mean age in the demented groups from the Brain Bank. The exception 
was the control group for hypercholesterolaemia, which included people aged 61 
to 70 years.  
Neuropathological assessment 
Macroscopic assessment of the brain included analysis of photographs. The right 
hemisphere was fixed in 4% formaldehyde for three weeks, while the left hemi-
sphere was dissected fresh. For diagnostic purposes, the following regions were 
dissected from the fixed right hemisphere and embedded in paraffin: frontal, cingu-
late, insular, temporal, parietal and occipital cortices including deep white matter; 
basal ganglia; thalamus; amygdala; hippocampus and entorhinal areas; mesen-
cephalon including substantia nigra; locus coeruleus and base of pons; medulla 
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oblongata; and cerebellum and cervical spinal cord (level C1 or C2). If necessary, 
selected parts of fixed remnants of the left hemisphere were also analysed. Cortical 
regions were routinely stained with haematoxylin and eosin, Bodian or Gallyas 
methods (for neurofibrillary tangles), methenamine-silver (for senile plaques), and 
Congo red (for congophilic plaques and vessels). Immunohistochemistry was per-
formed for alpha-synuclein (to detect Lewy bodies and Lewy neurites), AT8, beta 
A4, prion protein, ubiquitin and TDP43. 
The neuropathological diagnoses in our study were made on the basis of the 
following criteria. Vascular dementia was diagnosed if there was clinical dementia 
and the neuropathology corresponded to the classification by Brun and Gustafson 
(Brun et al., 1988)    and Brun (Brun et al., 1994).  . VaD diagnoses could include 
Alzheimer-related pathology at a Braak and Braak neurofibrillary tangles stage of III 
or lower, but no other neurodegenerative disorders (especially Lewy body patholo-
gies). Of the 40 cases of VaD, 16 showed small vessel disease with strategic infarcts 
(7 in the caudate, 7 in the thalamus and 2 in the parietal lobe), 19 had territorial 
infarcts (caused by large vessel disease) and 21 had white matter rarefaction 
and/or lacunar infarcts.  
Alzheimer’s Disease was diagnosed according to the criteria described by Braak 
and Braak, based on the presence, density and distribution of cortical neuritic 
plaques (Braak and Braak, 1997; Braak and Braak, 1990) and tangle pathology 
(Braak and Braak, 1991; Braak and Braak, 1990). We included only clinically de-
mented cases with Braak stages IV and V for neurofibrillary tangles, without any 
Lewy bodies. Seven of the 40 cases with AD showed focally reduced white matter 
density and/or one lacunar white matter infarct. These white matter lesions coex-
isting with AD were not considered to be severe enough to contribute to the de-
mentia, and these patients were therefore not included in the mixed dementia 
group.  
Mixed dementia was defined as meeting the criteria for VaD, combined with a 
Braak stage above III. Of the 40 cases diagnosed with MD, 6 showed territorial 
infarcts caused by large vessel damage, 22 decreased white matter density and/or 
lacunar infarcts caused by small vessel damage, and 12 a mixture of both large and 
small vessel damage. No strategic infarcts were found in the MD group.  
Statistical analysis  
Statistical analyses were performed using two different statistical packages. The 
Statistical Package for the Social Sciences (SPSS, Chicago, IL) version 16.0 for Win-
dows was used to compare the three groups in our own sample in terms of demo-
graphic variables. The following statistical tests were performed: ANOVA (with a 
general linear model) for continuous variables such as mean age and duration of 
dementia, and chi-square tests for categorical variables such as sex and the pres-
ence of each risk factor. The Statcalc module of Epi Info (version 6, November 
1993; CDC, Atlanta, GA) was used to compare risk factor percentages between all 
 50 
groups (including the control groups) using chi-square tests, and using Fisher’s 
exact test for numerical values. The results were expressed as odds ratios for 
prevalence, confidence intervals (95%) and p-values.  
Results  
Demographic variables 
The demographic characteristics (age and sex) of the cases and the duration of 
dementia are summarized in Table 1. No significant differences between AD and 
VaD were found for these variables. However, the mean age of the MD group was 
significantly higher than that of the AD and VaD groups. The longest mean duration 
of dementia was found for VaD (8 years), followed by MD (6.5 years) and AD (6 
years), but these differences were not statistically significant. 
 
Table 1. Demographic variables in the three groups of demented cases 
 AD 
 n = 40  
VaD 
 n = 40  
MD 
 n = 40 
P 
Age in years; mean (SD) 79.7 (3.7) 77.7 (11.1) 82.5 (5) 0.017 
Female sex; n (%) 27 (67.5) 21 (52.5) 25 (62.5) 0.171 
Duration of dementia in years; mean (SD) 6 (3.2) 8 (4.8) 6.5 (4.6) 0.104 
Note. Group differences were assessed with ANOVA (for age and duration of dementia) and chi-square 
tests (for sex). AD = Alzheimer's disease; VaD = vascular dementia; MD = mixed dementia; p = p value; 
SD = standard deviation.  
Distribution of risk factors  
Tables 2 and 3 show the number of participants and prevalence of risk factors in all 
the groups studied. 
 
 
 
 51
Table 2. Number and (%) of participants and distribution of risk factors in the three groups of dement-
ed cases 
 AD   VaD   MD   
 Total 
n = 40 
Males 
n =13 
Females
n =27 
Total 
n = 40 
Males 
n =19 
Females
n = 21 
Total 
n = 40 
Males 
n = 15 
Females 
n = 25 
Hypertension 24  
(60%) 
6  
(46.2%) 
18 
(66.7%)
21 
(52.5%)
10 
(52.6%)
11 
(52.4%)
22 
(55%) 
8 
(53.3%) 
14 
(56%) 
Stroke history 7 
(17.5%) 
3 
(23.1%) 
4 
(14.8%)
29 
(72.5%)
16 
(84.2%)
13 
(61.9%)
18 
(45%) 
7 
(46.7%) 
11 
(44%) 
Diabetes 9 
(22.5%) 
3 
(23.1%) 
6 
(22.2%)
4 
(10%) 
1 
(5.3%) 
3 
(14.3%)
9 
(22.5%)
4 
(26.7%) 
5 
(20%) 
Atrial 
Fibrillation 
8 
(20%) 
3 
(23.1%) 
5 
(18.5%)
9 
(22.2%)
4 
(21.1%)
5 
(23.8%)
4 
(10%) 
0 
(0%) 
4 
(16%) 
Hypercholester-
olaemia 
8 
(20%) 
3 
(23.1%) 
5 
(18.5%)
3 
(7.5%) 
2 
(10.5%)
1 
(4.8%) 
4 
(10%) 
0 
(0%) 
4 
(15.1%) 
Smoking 10 
(25%) 
4 
(30.8%) 
6 
(22.2%)
3 
(7.5%) 
2 
(10.5%)
1 
(4.8%) 
3 
(7.5% 
1 
(6.7%) 
2 
(8%) 
Note. AD = Alzheimer´s disease; VaD = vascular dementia; MD = mixed dementia. 
 
Table 3. Number and (%) of participants and distribution of risk factors in the control groups 
 Number of cases Prevalence of risk factors 
 Total 
N 
Males 
n 
Females 
N 
Total 
n (%) 
Males 
n (%) 
Females 
n (%) 
Hypertension26 1792 618 1174 811 
(45.6%) 
225 
(36.4%) 
586  
(50.4%) 
Stroke history28 583 238 345 110 
(18.8%) 
51 
(21.4%) 
59 
(17.1%) 
Diabetes28 583 238 345 107 
(18.4%) 
42 
(17.6%) 
65 
(18.8%) 
Hypercholesterolaemia29 1167 580 587 288 
(24.7%) 
89 
(15.5%) 
199 
(34%) 
Atrial fibrillation27 1392 492 900 149 
(10.7%) 
68 
(13.8%) 
81  
(9.2%) 
Smoking30 959 603 356 95 
(9.9%) 
61 
(10.1%) 
34 
(9.5%) 
Note. Three first columns show total number of cases in each epidemiological group and the three last 
columns represent number and percentages of cases that had the risk factor. The numbers (26-30) 
correspond to the references to epidemiological studies from which control group data were obtained.  
 
Figure 1 displays the prevalence of risk factors in each group and the statistical 
differences between the groups, while Table 4 details differences between the 
groups, overall and stratified by sex. Hypertension was the most prevalent risk 
factor in AD and MD groups but not among those diagnosed with VaD. No signifi-
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cant differences in hypertension were detected between the groups, though there 
was a trend towards a higher prevalence of hypertension in AD compared to con-
trols, especially considering female AD cases and controls (Table 4). Similarly, for 
diabetes no significant differences or trends were found between groups. History 
of stroke was the most prevalent risk factor in VaD. For this variable, differences 
between groups were significant in all cases, except for the control and AD groups 
in which the prevalence was very similar. Regarding hypercholesterolaemia, there 
was a significant difference between the controls and both VaD and MD groups. 
Notably, this difference was completely attributable to the female control sub-
group in which the prevalence of hypercholesterolaemia was notably higher (com-
pare Fig. 1 with Table 4). Atrial fibrillation was significantly more common in the 
VaD than the control group and again this was completely attributable to a higher 
prevalence in the female subgroup (see Fig. 1 and Table 4). A non-significant trend 
towards a difference was found between female AD cases and controls, with more 
atrial fibrillation in AD females (Table 4). Finally, the prevalence of smoking was 
statistically significantly higher in AD cases than controls (Fig 1 and Table 4).  
 
0
1 0
2 0
3 0
4 0
5 0
6 0
7 0
8 0
9 0
1 0 0
H
yp
er
te
ns
io
n
S
tro
ke
 h
is
to
ry
D
ia
be
te
s
H
yp
er
ch
ol
es
te
ro
la
em
ia
At
ria
l f
ib
ril
la
tio
n
A D
M D
V a D
C o n t r o l
V a D  >  C     ( * )
V a D  >  A D   ( * )
V a D  >  M D  ( * )
M D   >  C     ( * )
M D   >  A D   ( * )
C  >  V a D  ( * )
C  >  M D  ( * )  ^
V a D  >  C  ( * )  ^
Figure 1. Distribution of vascular risk factors between groups. 
Note. The percentage of occurrence of vascular risk factors in the four groups: AD = Alzheimer's dis-
ease; MD = mixed dementia; VaD = vascular dementia and corresponding controls. Significant differ-
ences (*) are shown above the columns. ^ = the differences in hypercholesterolaemia and atrial fibrilla-
tion are solely attributable to the prevalence in the female cases (see Table 4). 
 
 Ta
bl
e 
4.
 D
iff
er
en
ce
s b
et
w
ee
n 
gr
ou
ps
.  
 
Hy
pe
rt
en
si
on
 
St
ro
ke
 h
is
to
ry
 
DM
 
Hy
pe
rc
ho
le
st
er
ol
ae
m
ia
 
At
ria
l f
ib
ril
la
tio
n 
Sm
ok
in
g 
 
O
R 
CI
 
p 
O
R 
CI
 (9
5%
)
p 
O
R 
CI
 (9
5%
)
p 
O
R 
CI
 (9
5%
)
p 
O
R 
CI
 
p 
O
R 
CI
(9
5%
) 
p 
C 
vs
 A
D 
To
ta
l 
1.
8 
0.
9-
3.
6 
0.
06
4 
0.
9 
0.
3-
2.
2 
0.
83
0 
1.
2 
0.
5-
2.
9 
0.
51
4 
0.
7 
0.
3-
1.
7 
0.
49
8 
2.
0 
0.
8-
4.
8 
0.
07
0*
 
3.
0 
1.
3-
6.
7 
0.
00
6 
C 
vs
 A
D 
M
al
es
 
1.
5 
0.
4-
5.
0 
0.
56
3*
 
1.
1 
0.
2-
4.
5 
0.
55
7 
1.
4 
0.
2-
5.
8 
0.
42
1 
1.
6 
0.
3-
6.
8 
0.
32
7*
 
1.
8 
0.
4-
7.
6 
0.
40
7 
3.
9 
1.
1-
13
.2
 
0.
03
8*
 
C 
vs
 A
D 
Fe
m
al
es
 
2.
0 
0.
8-
4.
8 
0.
08
5 
0.
8 
0.
2-
2.
1 
0.
50
5 
1.
2 
0.
4-
3.
3 
0.
66
6 
0.
5 
0.
1-
1.
5 
0.
23
8 
2.
3 
0.
7-
6.
6 
0.
09
6 
2.
7 
1.
0-
7.
1 
0.
04
9*
 
C 
vs
 V
aD
 T
ot
al
 
1.
3 
0.
6-
2.
6 
0.
36
4 
13
.7
 
6.
3-
30
.2
0.
00
0 
0.
4 
0.
1-
1.
4 
0.
18
1 
0.
2 
0.
0-
0.
8 
0.
01
2 
2.
4 
1.
0-
5.
4 
0.
02
5*
 
0.
7 
0.
1-
2.
5 
0.
43
5*
 
C 
vs
 V
aD
 M
al
es
 
1.
9 
0.
7-
5.
2 
0.
14
8 
19
.5
 
5.
0-
88
.1
0.
00
0 
0.
2 
0.
0-
1.
9 
0.
13
4*
 
0.
6 
0.
1-
2.
9 
0.
42
9*
 
1.
6 
0.
4-
5.
5 
0.
32
5*
 
1.
0 
0.
1-
4.
6 
0.
57
7*
 
C 
vs
 V
aD
 F
em
al
es
 
1.
0 
0.
4-
2.
8 
0.
82
2 
7.
8 
2.
8-
21
.9
0.
00
0 
1.
2 
0.
4-
3.
3 
0.
66
6 
0.
1 
0.
0-
0.
8 
0.
01
5*
 
3.
1 
1.
2-
5.
8 
0.
00
3 
0.
4 
0.
0-
3.
2 
0.
37
3*
 
C 
vs
 M
D 
To
ta
l 
1.
4 
0.
7-
2.
9 
0.
22
0 
4.
2 
2.
1-
8.
6 
0.
00
0 
1.
2 
0.
5-
2.
9 
0.
51
4 
0.
3 
0.
1-
1.
0 
0.
03
3 
0.
9 
0.
2-
2.
7 
0.
57
2 
0.
7 
0.
1-
2.
5 
0.
43
5*
 
C 
vs
 M
D 
M
al
es
 
2.
0 
0.
6-
6.
2 
0.
17
9 
3.
2 
3.
9-
10
.3
0.
03
2*
 
1.
7 
0.
4-
6.
1 
0.
28
1 
0.
0 
0.
0-
1.
9 
0.
08
5 
0.
0 
0.
0-
2.
1 
0.
11
1 
0.
6 
0.
0-
4.
7 
0.
54
5*
 
C 
vs
 M
D 
Fe
m
al
es
 
1.
2 
0.
5-
3.
0 
0.
54
7 
3.
8 
1.
5-
9.
4 
0.
00
2*
 
1.
0 
0.
3-
3.
1 
0.
52
8 
0.
3 
0.
1-
0.
9 
0.
04
4 
1.
9 
0.
5-
6.
1 
0.
19
0 
0.
6 
0.
0-
4.
7 
0.
55
5*
 
AD
 v
s V
aD
 T
ot
al
 
0.
7 
0.
2-
1.
9 
0.
49
8 
12
.4
 
3.
8-
42
.5
0.
00
0 
0.
3 
0.
0-
1.
1 
0.
12
9 
0.
3 
0.
0-
1.
5 
0.
19
4 
1.
1 
0.
3-
3.
8 
0.
78
4 
0.
2 
0.
0-
1.
0 
0.
06
9 
AD
 v
s V
aD
 M
al
es
 
1.
3 
0.
2-
6.
7 
0.
72
3 
17
.1
 
2.
3-
17
6.
3
0.
00
0 
0.
1 
0.
0-
2.
5 
0.
27
0*
 
0.
1 
0.
0-
2.
5 
0.
27
8*
 
1.
5 
0.
1-
12
.1
0.
61
8*
 
0.
2 
0.
0-
2.
2 
0.
16
3*
 
AD
 v
s V
aD
 F
em
al
es
 
0.
5 
0.
1-
2.
0 
0.
32
0 
7.
3 
19
.0
-4
8.
1
0.
00
0 
0.
5 
0.
1-
3.
2 
0.
37
6 
0.
5 
0.
1-
3.
2 
0.
71
1*
 
0.
7 
0.
1-
3.
5 
0.
46
0*
 
0.
1 
0.
0-
1.
7 
0.
11
7 
AD
 v
s M
D 
To
ta
l 
0.
8 
0.
3-
2.
1 
0.
82
1 
3.
8 
1.
2-
12
.3
0.
00
7 
1.
0 
0.
3-
3.
2 
1 
0.
4 
0.
1-
1.
8 
0.
34
7 
0.
4 
0.
1-
1.
8 
0.
34
7 
0.
2 
0.
0-
1.
0 
0.
06
6 
AD
 v
s M
D 
M
al
es
 
1.
3 
0.
2-
7.
7 
0.
70
4 
2.
9 
0.
4-
21
.0
0.
25
4*
 
0.
8 
0.
1-
6.
1 
0.
58
7*
 
- 
- 
0.
37
6 
- 
- 
0.
08
7*
 
0.
1 
0.
0-
2.
0 
0.
15
2*
 
AD
 v
s M
D 
Fe
m
al
es
 
0.
6 
0.
1-
2.
2 
0.
61
3 
4.
5 
1.
0-
21
.1
0.
02
0 
1.
1 
0.
2-
5.
2 
0.
84
4 
1.
1 
0.
2-
6.
2 
0.
55
1*
 
1.
1 
0.
2-
6.
2 
0.
55
1*
 
0.
3 
0.
0-
1.
9 
0.
25
1*
 
Va
D 
vs
 M
D 
To
ta
l 
1.
1 
0.
4-
2.
9 
0.
82
2 
0.
3 
0.
1-
0.
8 
0.
02
3 
2.
6 
0.
6-
11
.5
0.
22
5 
1.
3 
0.
2-
8.
4 
0.
50
0*
 
0.
3 
0.
0-
15
.5
0.
22
5 
1.
0 
0.
1-
5.
2 
1.
00
0*
 
Va
D 
vs
 M
D 
M
al
es
 
1.
0 
0.
2-
4.
9 
0.
76
0 
0.
1 
0.
0-
1.
0 
0.
03
0*
 
6.
5 
0.
5-
17
5.
8
0.
14
5*
 
0.
0 
0.
0-
5.
4 
0.
49
1*
 
0.
0 
0.
0-
1.
8 
0.
11
3 
1.
6 
0.
1-
20
.1
 
0.
82
9*
 
Va
D 
vs
 M
D 
Fe
m
al
es
 
1.
1 
0.
3-
4.
3 
0.
95
8 
0.
4 
0.
1-
1.
8 
0.
36
0 
1.
5 
0.
2-
9.
4 
0.
70
9 
3.
8 
0.
3-
97
.7
0.
35
6 
1.
2 
0.
2-
7.
5 
0.
52
5 
0.
5 
0.
0-
6.
8 
0.
87
5 
N
ot
e.
 C
 =
 c
on
tr
ol
 g
ro
up
; A
D 
= 
Al
zh
ei
m
er
´s
 d
ise
as
e 
gr
ou
p;
 M
D 
= 
m
ix
ed
 d
em
en
tia
 g
ro
up
; V
aD
 =
 v
as
cu
la
r d
em
en
tia
 g
ro
up
. C
hi
-s
qu
ar
e 
te
st
s w
er
e 
pe
rf
or
m
ed
 fo
r c
om
pa
ris
on
s 
be
tw
ee
n 
gr
ou
ps
, a
nd
 w
he
n 
re
qu
ire
d,
 F
ish
er
’s
 te
st
s (
*)
. O
R 
= 
pr
ev
al
en
ce
 o
dd
s r
at
io
; C
I =
 c
on
fid
en
ce
 in
te
rv
al
 (9
5%
); 
p 
= 
p 
va
lu
e;
 si
gn
ifi
ca
nt
 d
iff
er
en
ce
s (
p 
< 
0.
05
) a
re
 in
 b
ol
d 
53
 54 
Discussion  
In this clinico-neuropathological study, we compared the presence of vascular risk 
factors not only between AD, VaD and MD cases (disease groups), but also between 
the disease groups and elderly Dutch control groups of similar age. The importance 
of the latter comparison was that it might detect specific causal cofactors (amena-
ble to preventive treatment) for AD and VaD. The main results of the pairwise 
comparisons between groups are discussed below. 
AD vs. control group. Our comparison between the AD patients and the control 
group (Fig.1, Table 4) revealed no significant differences with respect to the pres-
ence of hypertension, stroke history, diabetes mellitus, hypercholesterolaemia or 
atrial fibrillation, with the notable exception of smoking, which was more common 
in AD patients. This could indicate that smoking is a causal factor for AD, but smok-
ing behaviour might also be disinhibited in AD, or caregivers might not discourage it 
in these patients. We were unable to find data in the patient records on smoking 
load in terms of pack years for the disease period. 
VaD vs. control group. the comparison between the VaD group and the control 
groups (Fig.1, Table 4) shows that a history of stroke appears to be more common 
in VaD. The high significance level evidently depended on the neuropathological 
(and clinical) definition of VaD. Previous studies have also found this positive rela-
tionship between history of stroke and VaD (Chiang et al., 2007; Erkinjuntti et al., 
2007). Hypercholesterolaemia was seen to be more common in the control group 
than in VaD (and in MD), while atrial fibrillation was more common in VaD cases. 
The difference in hypercholesterolaemia might be attributable to the female con-
trol subgroup, in which the prevalence of hypercholesterolaemia was much higher 
than in the female VaD and MD groups (compare Fig. 1 with Tables 3 and 4). If this 
is not a chance observation, we should explore why cholesterol levels are lower in 
female patients with VaD. Atrial fibrillation was significantly more common in the 
VaD group than the control group and this was apparently caused by a higher prev-
alence in the female VaD subgroup (see Fig. 1 and Tables 3 and 4). It remains un-
clear why it is especially women with VaD who have atrial fibrillation. 
MD vs. control group. Our comparison of MD with the control groups produced 
results similar to the comparison of VaD with its controls, with the exception of the 
prevalence of atrial fibrillation, which was not significantly different between MD 
cases and controls.  
Comparison of the disease groups with each other did not reveal any signifi-
cantly different frequencies for any of the risk factors, with the exception, again, as 
could be expected, for history of stroke. The largest differences in this variable 
were seen between VaD and controls, and between VaD and AD. 
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A look at the columns in Table 4 shows that we did not detect any statistically 
significant differences between the disease groups for the risk factor of hyperten-
sion. The prevalence of hypertension was relatively high, between 52.5% and 
60.0% in the disease groups and 45.6% in the control group. Although none of the 
differences reached the significance level, the comparison between AD and control 
groups showed a trend towards high rates of hypertension in AD, once again at-
tributable to the female subgroup. 
Notably, although diabetes mellitus is an important co-determinant of vascular 
disease, rates of diabetes were not significantly different between the disease 
groups or between the disease groups and controls, and there was not even any 
detectable trend. This might be due to the relatively small number of patients in 
the groups with dementia (see Table 2), but another explanation, which we consid-
er highly plausible, is that diabetes is effectively treated in the Netherlands, which 
may have prevented strokes.  
To the best of our knowledge, our study is the first on this topic (prevalence of 
several vascular risk factors in AD, VaD and MD) to use a sample of cases with neu-
ropathological confirmation of the diagnoses of dementia. Accordingly, no compar-
ison can be made with previous studies, except with some that were performed in 
vivo. All in vivo studies that we found were longitudinal epidemiological investiga-
tions, and many of them supported the view that there is a relationship between 
vascular risk factors and dementia (Pohjasvaara et al., 1998; Kivipelto et al., 2001; 
Kivipelto et al., 2005; Knopman et al., 2001; Kuller et al., 2005; Reitz et al., 2008; 
Skoog et al., 1996). In particular, some studies examining the implications of hyper-
tension found an association between this risk factor and late-life VaD (Lindsay et 
al., 1997) and AD (Skoog et al, 1996). Hypertension in midlife has been associated 
with VaD and AD  and with the number of neuritic plaques and neurofibrillary tan-
gles (Petrovich et al., 2000). The study by Petrovitch et al. examined the relation-
ship between blood pressure levels and the number of neuropathological lesions of 
AD using counts of neuritic plaques and neurofibrillary tangles as endpoints, not 
AD, which means that this study is not strictly comparable to ours. Similarly, Launer 
et al (Launer et al., 2001) found an association between late-life HDL cholesterol 
levels and the formation of neuropathological lesions of AD, irrespective of demen-
tia.  On the other hand, other researchers, whose studies focused on the aeti-
opathogenesis of dementia, found no evidence of a causal relationship between 
vascular risk factors and dementia (Launer et al., 2008; Purnell et al., 2009; Richard 
et al., 2009). Frequent clinical dementia (AD, Lewy body dementia and VaD) cases 
are known to often comprise mixed conditions with Alzheimer’s, vascular and Lewy 
body pathologies (Echávarri et al., 2012; Jellinger et al., 2003; Knopman et al., 
2010). This would not only explain the inconsistent results of in vivo studies into 
the relationship between vascular risk factors and dementia, but also the difficulty 
of identifying vascular risk factor patterns associated with subtypes of dementia 
 56 
(AD, VaD or MD). In this respect, a history of stroke is a risk factor for VaD, as has 
been assumed by other researchers and is supported by our findings (Erkinjuntti et 
al., 1988). 
Some methodological issues have to be addressed. While clinical studies can be 
strictly controlled and prospective, neuropathological confirmation is often lacking. 
On the other hand, a clinico-pathological study like ours is necessarily retrospec-
tive, meaning that clinical parameters (like total serum cholesterol) are not always 
available or compiled consistently, and brain bank donation is not strictly con-
trolled. Nevertheless, the availability of a neuropathological diagnosis is a consider-
able advantage. While Alzheimer’s disease is the most frequent cause of dementia, 
a clinico-pathological study like ours can distinguish between pure AD and VaD 
cases. It is important to note that establishing a neuropathological diagnosis of VaD 
is a controversial issue, since no clear criteria have so far been established in the 
literature (Esiri et al., 1997). In fact, prior studies based on neuropathological series 
of demented patients have reported low prevalence of pure VaD, between 2 and 
10%. The NBB database for 1984 to 2010 includes 660 AD cases but only 40 “pure” 
VaD cases. This  underlines the value of the fact that our study comprised a sample 
of 40 cases with pure VaD (Jellinger et al., 2007). 
A major weakness of our study is, however, the relatively small number of cas-
es (three times n=40), which was determined by the lack of VaD cases. We recog-
nise that these small numbers may explain why we found so few statistically signifi-
cant differences between groups for the vascular risk factors considered, and many 
relationships remained unclear, except for some indications from the non-
significant trends we detected (see Fig. 1 and Table 4). We could not prove that 
there are causal relations between risk factors and AD, VaD and MD, but, on the 
other hand, neither could we disprove them. Therefore, future meta-analytical 
studies are needed for further statistical testing.  
Another weakness of our study is the partial lack of homogeneity in both of the 
samples (demented and control) we compared. Despite differences in the selection 
processes of the patients included in the study sample and the lack of neuropatho-
logical assessment among the controls, we still consider that our comparison of 
these two samples has yielded results that are worthy of serious consideration. On 
the one hand, we assume that the control groups include two different subgroups: 
a subgroup that will never become demented and a non-demented subgroup that 
will become demented in the future. On the other hand, all subjects in the disease 
groups were demented. Thus, we consider that if risk factors play a role in demen-
tia, they would be more concentrated in the disease groups, as the control groups 
included subgroups of people who would never become demented. Moreover, we 
used controls of ages similar to those of the disease groups and have also examined 
men and women separately, making both samples more homogeneous.  
We conclude that our clinico-neuropathological study was unable to detect incre-
ased prevalences of vascular risk factors in AD except for a higher proportion of 
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smokers. Among VaD patients, we observed that a history of stroke was more 
common in the total group (men and women).The rates of hypercholesterolaemia 
were higher in the female controls than in the female VaD patients, and the rates 
of atrial fibrillation were higher in the female VaD patients than in the female con-
trols. Overall, however, our approach using neuropathological confirmation of 
dementia diagnoses seemed to make most of the previously reported group diffe-
rences in vascular risk factors disappear. We argue that none of the risk factors we 
examined may be related to the presence of dementia, except for stroke history in 
VaD.  
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Neuropsychiatric symptoms (NPSs) have a large impact on the quality of life of 
patients with dementia. A few studies have compared neuropsychiatric disturban-
ces between dementia subtypes, but the results were conflicting. In the present 
study, we investigated whether the prevalence of NPSs differs between Alzheimer’s 
disease (AD) and vascular dementia (VaD). The merit of our study is that we used 
clinical as well as histopathological information to differentiate between dementia 
subtypes. This retrospective descriptive study comprised 80 brains obtained from 
donors to the Netherlands Brain Bank (NBB) between 1984 and 2010. These donors 
were diagnosed post-mortem with AD (n = 40) or VaD (n = 40). We assessed the 
presence of NPSs by reviewing the information found in the patients’ medical files. 
The most prevalent symptom in the sample as a whole was agitation (45 cases, 
57.0%), followed by depression (33, 41.2%) and anxiety (28, 35.4%). Our study tried 
to contribute to the discussion by including, for the first time in the literature, a 
sample of AD and VaD patients with neuropathologically confirmed diagnoses. 
Since no significant differences were found between AD and VaD patients, we sug-
gest that the prevalence of NPSs cannot be predicted from the dementia diagnosis 
of AD or VaD.  
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Introduction 
Neuropsychiatric symptoms (NPSs) are increasingly recognized as an important and 
intrinsic aspect of the dementia syndrome [1,2,3,4,5,6]. These symptoms have a 
large impact on the quality of life of patients with dementia, and have been associ-
ated with increased caregiver burden, more rapid progression of cognitive and 
functional decline, earlier institutionalization and even increased mortality [7]. 
Several studies have found that NPSs are common in patients with Alzheimer’s 
disease (AD) and vascular dementia (VaD) [8,9,10,11,12,13,14,15], with apathy, 
depression, anxiety and agitation/aggression having been most frequently reported 
[16,9,18,4,19,6,20,21,22,23].  
It is important to know whether different types of dementia present different 
neuropsychiatric profiles, because these differences could affect caregiver distress 
[15]. In addition, this knowledge may lead to more effective treatment, and to 
further insights into brain-behaviour relationships. A few studies have compared 
neuropsychiatric disturbances between dementia subtypes, and so far, the results 
have been conflicting. Some studies found higher prevalences of NPSs in VaD, in-
cluding affective disturbances such as depression, anxiety or agitation 
[16,9,24,25,13]; other studies found higher prevalences in AD, including anxiety 
and agitation [10,18]; and still others found no differences between groups 
[12,21,14]. This makes it difficult to establish a pattern of NPSs in different sub-
types of dementia.  
These contradictory results may be due to a lack of accuracy in diagnosing de-
mentia subtypes  [26,4,27,20,28,22,29]. Clinical diagnoses made in vivo often differ 
from the neuropathological diagnoses established post-mortem [30,31]. Hence, 
comparisons of NPSs between dementia subtypes should preferably include neuro-
pathological information. In the present study, we investigated whether the preva-
lence of NPSs differs between AD and VaD. We focussed on 12 psychiatric symp-
toms, which are those assessed by Neuropsychiatric Inventory [32] (delusions, 
hallucinations, agitation, depression, anxiety, euphoria, apathy, disinhibition, irrita-
bility, aberrant motor behaviour, night-time behavioural disturbances and appetite 
changes). We examined the prevalence of NPSs in 80 patients for whom a neuropa-
thological diagnosis of AD or VaD had been established. The merit of our study is 
that we used clinical as well as histopathological information to differentiate be-
tween dementia subtypes.  
Materials and Methods 
Participants 
This retrospective descriptive study comprised 80 brains obtained from donors of 
the Netherlands Brain Bank (NBB) between 1984 and 2010. During this period of 
 64 
time, 660 cases of AD and 40 cases of VaD were diagnosed at the NBB. All 40 VaD 
cases were included in this study, while 40 AD cases were matched for age with the 
VaD cases. Demographic data are presented in Table 1. The clinical dementia rating 
(CDR) score was assessed before death; presence of comorbidity included the pre-
sence of any vascular risk factor (hypertension, diabetes, hyperlipidaemia or atrial 
fibrillation) or any systemic disorder.  
 
Table 1. Demographic data 
  VaD (n = 40) AD (n = 40)   p 
Age (years); mean (SD) 77.7 (11.1) 77.8 (2.7) 0.947 
Sex (% women) 52.5 60.0 0.254 
Duration of illness (years); mean (SD) 8 (4.8) 6 (3.2) 0.037 
Number of NPSs; mean (SD) 2.3 (1.6) 2.2 (1.2) 0.836 
CDR score prior to death  2.8 (0.3) 2.9 (0.3) 0.251 
Prior history of depression n (%) 5 (16.6) 3 (7.5) 0.456 
Comorbidity n (%) 38 (95.0) 39 (97.5) 0.556 
Nursing home n (%) 14 (35.0) 21 (52.5) 0.114 
Medication – sleep disorder n (%) 8 (20.0) 13 (32.5) 0.598 
Medication – antidepressant n (%) 9 (22.5) 9 (22.5) 1.000 
Medication – behavioural disorder n (%) 17 (42.5) 13 (32.5) 0.355 
The group differences (between VaD and AD) were calculated with ANOVA for age and duration of 
illness, and with Chi-square for sex, previous history of depression, presence of comorbidity, living in a 
nursing home, antidepressant medication, and medication for sleep disorder or for behavioural disor-
ders. The Mann–Whitney test was used for the CDR score. VaD = vascular dementia; AD = Alzheimer´s 
disease; duration of illness = years from onset of symptoms to death; p = p-value; SD = standard devia-
tion.  
 
All clinical data were obtained from the patient’s GP, the doctor at the nursing 
home, neurologists or psychiatrists. All patients were diagnosed with dementia, 
defined as any irreversible and progressive cognitive impairment affecting at least 
one cognitive domain and interfering with the patient’s daily life. Patients were 
selected according to the neuropathological diagnoses (VaD and AD); all of them 
had a clinical diagnosis of dementia, but not all neuropathological diagnoses were 
in agreement with clinical diagnoses. In fact, the clinical diagnoses of the 40 cases 
with a neuropathological diagnosis of VaD were as follows: 25 (62.5%) VaD, 7 
(17.5%) AD, 6 (15%) mixed dementia, 1 (2.5%) frontotemporal lobar dementia and 
1 (2.5%) Lewy body dementia, while the clinical diagnoses of the 40 cases with a 
neuropathological diagnosis of AD were as follows: 28 (70%) AD, 8 (20%) VaD, 3 
(7.5%) Lewy body dementia and 1 (2.5%) frontotemporal lobar dementia.  
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The neuropathological diagnoses were obtained by an experienced neuro-
pathologist. The criteria used for neuropathological diagnoses were as follows: AD 
was diagnosed according to the criteria described by Braak and Braak, based on the 
presence, density and distribution of cortical neuritic plaques [33,34] and tangle 
pathology [35,34].  Braak stages of AD-related neurofibrillary tangle pathology 
were between IV and VI (8 cases [20%] at Braak stage IV, 14 [35%] at stage V, and 
18 [45%] at stage VI). VaD was diagnosed according to the classification of Brun and 
Gustafson [17] and Brun [36] with a Braak stage for neurofibrillary tangles ≤ III. Of 
the 40 cases of VaD, 16 showed strategic small vessel infarcts (7 in the caudate, 7 in 
the thalamus and 2 in the parietal lobe), 19 showed territorial infarcts (caused by 
large vessel pathology) and 21 showed white matter rarefaction and/or lacunar 
infarcts. The severity of the vascular pathology (i.e. staging of the vascular lesions) 
was assessed according to the classification used by Jellinger et al. (see Table 2) 
[37], ranging from 0 to 3. In our VaD sample, 19 brains had a score of 3, 17 partici-
pants a score of 2 and 4 a score of 1. In the AD sample, 38 participants showed no 
vascular lesions (VL) (score of 0) and 2 a score of 1, but no strategic infarcts were 
found, and in these two cases VL was considered not to be severe enough to have 
contributed to the dementia. In order to obtain a more homogeneous distribution 
of participants in the VaD group, two subgroups were distinguished: 19 brains with 
large vessel vascular disease (LV VaD) (mean age = 81.3, SD age = 8, percentage 
women = 52), and 21 brains with small vessel vascular disease (SV VaD) (mean age 
= 74.4, SD age = 12.6, percentage women = 52.4). LV VaD was diagnosed when the 
brain showed more than one large vessel infarct; SV VaD was diagnosed when 
moderate (subjectively assessed) white matter damage and more than one lacunar 
infarct were present (this group also included vasculitis [n=1], amyloid angiopathy 
[n=1] and isolated strategic infarcts). 
Exclusion criteria were neuropathological diagnoses of other neuro-
degenerative diseases than AD or VaD (other tauopathies, Lewy body pathology), 
mixed AD and VaD, and the presence of any tumoural lesion. Written informed 
consent was obtained from all patients or their relatives.  
Neuropsychiatric assessment 
We assessed the presence of 12 NPSs – delusions, hallucinations, agitation, depres-
sion, anxiety, euphoria, apathy, disinhibition, irritability, aberrant motor behaviour, 
night-time behavioural disturbances and appetite changes – based on the informa-
tion in the patients’ medical files. The clinical information was collected as follows: 
symptoms were considered to be present when their presence was recorded in the 
medical files or in case of any treatments (e.g. antidepressants) for such symptoms, 
and absent when no mention of the symptom was found in the patient´s file. In 
many cases, the patient records did not allow a distinction to be made between 
depressive symptoms and depressive disorders, nor was sufficient information 
available on the severity of NPSs. Information was collected regarding the frequen-
cy of symptoms, the tendency of symptoms to recur or persist, and the medication 
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used to treat the NPS. These medications included three groups. The first consisted 
of those used in sleep disorders, including short-acting benzodiazepines and tra-
zodone, which is an antidepressant with sedative properties, while the second 
group comprised antidepressants, including selective serotonin uptake inhibitors 
(SSRIs) and others, used to treat depression or depressive symptoms, anxiety and 
irritability. The third group comprised medications for behavioural disorders, which 
are neuroleptic (typical and atypical), usually used to treat agitation. Atypical anti-
psychotic agents (risperidone, olanzapine, quetiapine) were generally used more 
often than the typical ones. In some cases medication for an NPS was used though 
the presence of the symptom was not reported the medical file, and no informati-
on was provided about the symptom or symptoms that this medication was pre-
scribed for. In view of this, we set the following criteria for determining the presen-
ce of a symptom, based on the most common use of medications for NPSs: users of 
antidepressants were regarded as suffering from depressive symptoms, users of 
benzodiazepines or trazodone at night were regarded as suffering from sleep or 
night-time behavioural disturbances, users of benzodiazepines were regarded as 
suffering from anxiety and users of neuroleptics were regarded as suffering from 
agitation. A symptom was considered to be recurrent when more than one episode 
was reported, and was considered to be persistent when the symptom was re-
ported to last for more than one week. The average time between the last as-
sessment of NPSs and death was 5.6 months, with a range of 1 month to 2 years.   
Histopathological procedure  
Macroscopic assessment of the brain included photographs. The right hemisphere 
was fixed in 4% formaldehyde for 3 weeks. The left hemisphere was freshly dissec-
ted in particular pieces for the Netherlands Brain Bank applicants. For diagnostic 
purposes, the following regions were dissected from the fixed right hemisphere 
and embedded in paraffin: frontal, cingulate, insular, temporal, parietal and occipi-
tal cortices, including deep white matter; basal ganglia; thalamus; amygdala; hip-
pocampus and entorhinal areas; mesencephalon including substantia nigra; locus 
coeruleus; medulla oblongata; cerebellum and cervical spinal cord (level C1 or C2). 
If necessary, selected parts of the fixed remnants of the left hemisphere were also 
analysed. Cortical regions were routinely stained with HE, Bodian or Gallyas, me-
thenamine-silver, and Congo. Tau (AT 8) immunohistochemistry was applied routi-
nely in every case. Immunohistochemistry for alpha-synuclein was routinely per-
formed to identify Lewy body pathology, while beta A4, prion protein, ubiquitin 
and TDP43 immunohistochemistry were used when required.  
Statistical analysis  
Statistical analyses were performed using the Statistical Package for the Social 
Sciences (SPSS Inc, Chicago), version 16.0 for Windows. Demographic data were 
compared between groups, using ANOVA (General Linear Model; GLM) for conti-
nuous variables such as mean age and duration of illness; chi-square for categorical 
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variables such as sex, previous history of depression, presence of comorbidity, 
living in a nursing home, antidepressant medication, medication for sleep disorder 
or medication for behavioural disorders; and Mann–Whitney for ordinal variables 
such as CDR score. Logistic regression analysis was used to test the association 
between each neuropsychiatric symptom (independent variable) and the type of 
dementia (dependent variable), including duration of illness and age as covariates. 
Results are presented as odds ratios (OR) with 95% confidence intervals (95% CI). 
The significance level was set at p < 0.05 for all analyses.  
Results 
The only statistically significant difference in demographic variables between the 
two diagnostic groups regarded duration of illness (p < 0.05). The most prevalent 
symptom in the sample as a whole was agitation (45 cases, 57.0%), followed by 
depression (33, 41.2%) and anxiety (28, 35.4%). Figure 1 shows the prevalence of 
each NPS in the two groups, while the tendency to persist and the need for phar-
macological treatment are shown in Table 3. No significant differences between the 
groups were found, although depression was slightly more frequent in the VaD 
group (50%, vs. 32.2% in the AD group). The values of OR, CI (95%) and p for diffe-
rences between groups were: delusions (OR 0.4; CI [95%] 0.0-1.9; p = 0.266); hallu-
cinations (OR 1.1; CI [95%] 0.3-1.9; p = 0.849); agitation (OR 1.6; CI [95%] 0.6-4.1; p 
= 0.290); depression (OR 0.5; CI [95%] 0.2-1.3; p = 0.202); anxiety (OR 1.5; CI [95%] 
0.5-3.8; p = 0.392); euphoria (OR 0.6; CI [95%] 0.0-7.6; p = 0.710); apathy (OR 0.4; 
CI [95%] 0.1-1.3; p = 0.153); disinhibition (OR 0.1; CI [95%] 0.0-1.0; p = 0.063); irri-
tability (OR 0.4; CI [95%] 0.0-2.3; p = 0.312); aberrant motor behaviour (OR 1.2; CI 
[95%] 0.3-4.3; p = 0.621); night-time behavioural disturbances (OR 2.7; CI [95%] 
0.5-12.7; p = 0.193) and appetite changes (OR 1.2; CI [95%] 0.3-4.3; p = 0.601). 
When we excluded duration of illness as a covariate from the analysis, we still did 
not find significant differences. Results regarding the subgroups of VaD showed no 
differences between the two subgroups (LV VaD and SV VaD) or between each 
subgroup and AD.  
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Figure 1. Prevalence of neuropsychiatric symptoms in AD and VaD  
Distribution, in numbers, of neuropsychiatric disturbances; AD = Alzheimer´s disease; VaD = vascular 
dementia.  
 
Table 2. Classification of vascular lesions (VL) 
0 No concomitant VL 
1 Minimal VL: 1-2 small lacunae, mild–moderate cerebral amyloid angiopathy (CAA), mild VL, 
mild leukoencephalopathy 
2 Moderate VL: >2 lacunae, severe subcortical lacunar state, severe CAA with moderate VL, 
diffuse white matter lesions 
3 Severe VL: (a) Old infarcts, multiple old microinfarcts or haemorrhages, hippocampal sclerosis; 
(b) acute ischaemic infarcts, haemorrhages (<1-2 days old) 
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Table 3. Numbers of NPSs, tendency to persist and need for medication in each group. 
 AD (n =40) VaD (n=40) 
 n  Recurrent 
or persistent 
cases 
Treated with 
medication 
n  Recurrent 
or persistent 
cases 
Treated with 
medication 
Delusions 3 0 0 6 2 0 
Hallucinations 10 6 5 7 4 2 
Agitation 24 20 12 21 18 17 
Depression 13 6 9 20 10 9 
Anxiety 16 14 12 12 9 10 
Euphoria 1 1 0 2 0 0 
Apathy 9 9 0 15 12 0 
Dishinibition 3 2 0 8 1 0 
Irritability 2 2 2 5 3 3 
Aberrant motor behaviour 7 6 5 6 6 5 
Night-time behavioural  
disturbances 
4 4 2 3 3 3 
Appetite changes 0 0 0 1 1 0 
AD = Alzheimer´s disease; VaD = Vascular dementia. A symptom was considered to be recurrent when 
more than one limited episode was reported, and was considered to be persistent when the symptom 
was reported to last for more than one week.  
Discussion 
Our study did not reveal any significant differences in the prevalence of NPSs bet-
ween AD and VaD. A few earlier studies have compared NPSs in AD and VaD using 
the Neuropsychiatric Inventory (NPI). These studies found no consistent differences 
between dementia subtypes either: Aharon-Peretz et al. [16], Hsieh et al. [25]  and 
Ballard et al. [9]  found higher prevalences of apathy, agitation, depression and 
anxiety in VD; Caputo et al. [18]  found a higher prevalence of anxiety in AD; and 
Fuh et al. [4], Srikanth et al. [21], Johnson et al. [12]  and Hargrave et al. [19]  found 
no differences between the two groups. These were all in vivo studies, which did 
not use neuropathological confirmation of the diagnoses, increasing the risk of 
misdiagnoses or comorbidity of other pathologies. The added value of the present 
retrospective study is that, although we could not use standardized tools for asses-
sing the presence and severity of NPSs, we did use neuropathological confirmation 
of the diagnosis, and can therefore claim to have included “pure” cases of vascular 
and Alzheimer type dementia. Besides, it is routine clinical practice to ask questions 
about NPSs in history-taking, which means that the information about the presence 
or absence of NPSs that we obtained from the patients’ files was, from our point of 
view, accurate and reliable. It is important to take into account that some symp-
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toms are likely to have been gathered with greater reliability than others. In parti-
cular, we presume that depression, anxiety and agitation, which are frequent and 
easily detectable, will have received greater attention from the clinicians in their 
routine clinical practice than the other symptoms.  
Our retrospective study thus had two important limitations, the first one re-
garding the lack of standardized tools for clinical variables and the second regard-
ing the small number of cases; both could have resulted in a lack of power to ob-
serve any differences. Although a trend towards a difference between AD and VaD 
might be suggested for some symptoms (depression, apathy, disinhibition), Figure 
1 shows that the above limitations may explain why we did not find any statistically 
significant differences. We failed to prove that there are causal relations between 
NPSs and subtypes of dementia, but neither could we reject them. On the other 
hand, our study had the advantage of the availability of post-mortem tissue and 
neuropathological confirmation of the diagnoses.  
We would like to draw attention to the higher (though not significantly so) 
prevalence of depression among the VaD patients in our study. Depression has 
been attributed to disruptions of cortico-subcortical circuits, involving basal gan-
glia, thalamus and frontal lobes. Vascular damage can disturb these cortico-
subcortical circuits with lacunar lesions and white matter ischaemic injury 
[9,38,39]. Although these pathological processes are also present in AD, they are 
more prominent in VaD [40], which might explain why the prevalence of depression 
was slightly higher in our VaD group. 
As regards the VaD group, we had surmised that neuropsychiatric disturbances 
might depend on the type of VL, but we did not find any differences either between 
the subgroups of VaD or between these subgroups and the AD group. This lack of 
significant differences might be due again to the small size of the sample. In view of 
this, we have to take into account the low prevalence of pure VaD in the general 
population. The NBB sample included only 40 cases diagnosed with pure VaD, while 
660 AD cases were diagnosed in the same period of time. We also note the consid-
erable heterogeneity of VL in our VaD group. Since VaD is quite a rare diagnosis, it 
was impossible for us to compose more homogeneous vascular groups that were 
large enough for proper statistical analyses. Therefore, our conclusions apply to the 
heterogeneous group which is called VaD but which is not a pure nosologic entity. 
In this respect, our approach is similar to that used in previous studies [40,41]. 
In conclusion, our data suggests that NPSs are related to dementia in a non-
specific way, that is, AD and VaD patients do not differ significantly in terms of the 
12 NPSs we included in our analysis. It is therefore important to investigate these 
NPSs in each demented patient individually, in order to improve the therapeutic 
approach and decrease caregiver burden as much as possible. We want to stress 
that previous studies were based on clinical diagnoses, which were probably often 
not accurate, especially with respect to VaD. Our study is the first one in the litera-
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ture to provide an assessment of NPSs in subtypes of dementia based on clinical as 
well as neuropathological diagnoses.  
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CHAPTER 6 
Atrophy in the parahippocampal gyrus 
as an early biomarker of Alzheimer’s 
disease 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C. Echávarri, P. Aalten, H.B.M. Uylings, H.I.L. Jacobs, P.J. Visser, E.H.B.M. 
Gronenschild, F.R.J. Verhey and S. Burgmans. Atrophy in the parahippocampal 
gyrus as an early biomarker of Alzheimer’s disease. Brain Struct Funct (2011) 
215:265–271. 
 76 
The main aim of the present study was to compare volume differences in the hip-
pocampus and parahippocampal gyrus as biomarkers of Alzheimer’s disease (AD). 
Based on previous findings, we hypothesized that there would be significant vol-
ume differences between cases of healthy aging, amnestic mild cognitive impair-
ment (aMCI), and AD. Furthermore, we hypothesized that there would be larger 
volume differences in the parahippocampal gyrus than in the hippocampus. In 
addition, we investigated differences between the anterior, middle, and posterior 
parts of both structures.We studied 3 groups of male participants: 18 healthy par-
ticipants without memory decline; 18 patients with aMCI; and 18 patients with AD. 
3T T1-weighted MRI scans were acquired and gray matter volumes of the anterior, 
middle, and posterior parts of both the hippocampus and parahippocampal gyrus 
were measured using a manual tracing approach.Volumes of both the hippocam-
pus and parahippocampal gyrus were significantly different between groups in the 
following order: healthy > aMCI > AD. Volume differences between the groups 
were relatively larger in the parahippocampal gyrus than in the hippocampus, in 
particular when we compared healthy controls with individuals with aMCI. No sub-
stantial differences were found between the anterior, middle, and posterior parts 
of both structures. Our results suggest that parahippocampal volume discriminates 
better than hippocampal volume between cases of healthy aging, aMCI, and AD, in 
particular in the early phase of the disease. The present results stress the im-
portance of parahippocampal atrophy as an early biomarker of AD. 
 
 
 77
Introduction 
Atrophy in the medial temporal lobe has repeatedly been associated with age-
related memory decline, mild cognitive impairment (MCI), and dementia (Burg-
mans et al., 2009; Hackert et al., 2002; Laakso et al., 2000; Raz et al., 2005; Scher et 
al., 2007; van de Pol et al., 2006; Visser et al., 2002; Wang et al., 2006). This is par-
ticularly true for hippocampal atrophy, which is considered to be one of the best 
predictors of Alzheimer’s disease (AD) (Detoledo-Morrel et al., 1997; Jack et al., 
2010; Jack et al.,1997; Pennanen et al., 2004). Recent findings suggest, however, 
that parahippocampal atrophy might have more potential as a predictor of AD.  
Previous histological studies have already shown that the earliest neuro-
pathological changes in AD appear in the entorhinal cortex, which is the anterior 
part of the parahippocampal gyrus (Braak and Braak 1990; Van Hoesen 1982). At 
present, several MRI studies suggest that volume measures of the entorhinal cortex 
provide higher sensitivity than volume measures of the hippocampus when it 
comes to detecting AD in an early phase of the disease (Detoledo-Morrel et al., 
2004; Dickerson et al., 2001; Pennanen et al., 2004). Despite these findings, the 
parahippocampal gyrus has until now received much less attention than the hippo-
campus as an early predictor of AD. Moreover, the total parahippocampal volume - 
including posterior parts of the gyrus - has rarely been investigated in clinical popu-
lations. There is only scant evidence that this posterior part is involved in age-
related and pathological changes (Burgmans et al., 2009; Insausti et al., 1998; 
Thangavel et al., 2008; Weniger and Irle 2006).  
There is some evidence that the amount of atrophy differs between anterior, 
middle and posterior areas of the hippocampus and parahippocampal gyrus. One 
hypothesis is that differences in the amount of atrophy along the longitudinal axis 
are caused by the way cortical connections are organized. Van Hoesen et al. (1982) 
and Insausti and Amaral (2008) concluded from nonhuman primate studies that the 
posterior parahippocampal gyrus plays a key role in the information flow between 
cortical association areas and the hippocampal formation. There are massive pro-
jections from the posterior parahippocampal areas TF and TH to the rostral portion 
of the entorhinal cortex. Since the entorhinal cortex is reciprocally connected to 
the anterior hippocampus, we may speculate that damage in the posterior para-
hippocampal gyrus can lead to tissue changes in the anterior hippocampus. How-
ever, more research is needed to reveal the mechanism of differential decline in 
the medial temporal lobe structures. 
In the present study, we compared volume differences in the hippocampus and 
parahippocampal gyrus in three groups of older individuals: healthy controls, indi-
viduals with amnestic MCI, and patients with AD. We hypothesized that volume 
differences between these groups are larger in the parahippocampal gyrus than in 
the hippocampus. In addition, we investigated differences between the anterior, 
middle, and posterior parts of both structures.  
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Materials and Methods 
Participants  
Three groups of older male participants were included in this study: healthy partic-
ipants without memory impairment, patients with amnestic MCI (aMCI) and pa-
tients with AD. The healthy participants were recruited by means of advertise-
ments in local newspapers. They were administered an extensive neuropsychologi-
cal test battery and were included if their performance did not deviate from normal 
on the Verbal Learning Test (Folstein et al., 1975; Van der Elst et al., 2005). The 
patients with aMCI or AD were recruited from the Memory Clinic of the Maastricht 
University Hospital. All the diagnoses were made by a multidisciplinary team under 
supervision of an experienced neuropsychiatrist from the Memory Clinic (FRJV) 
according to the Petersen criteria for aMCI (with at least an impairment in the 
memory domain)(Petersen et al., 2001; Petersen et al., 1999), and according to the 
DSM-IV and NINCDS-ADRDA criteria for AD (McKhann et al., 1984). The diagnoses 
were based on medical history, co-morbidity, course, and MRI scan. The MRI scan 
was used to exclude vascular pathology; levels of atrophy were not used for the 
diagnosis of aMCI and AD. 
The exclusion criteria were: use of psychoactive medication; abuse of alcohol and 
drugs; other past or present psychiatric or neurological diseases or serious system 
diseases; and structural abnormalities in the brain that could account for the cogni-
tive decline. Two participants in the control group were excluded because a brain 
infarct was detected on the MRI scans and two patients in the AD group were ex-
cluded because their MRI images showed motion artefacts. The remaining number 
of participants (after excluding these 4 subjects) was 18 per group. Thus the final 
population consisted of: 18 healthy male participants (mean age = 64.5 years, SD 
age = 3.3 years); 18 male patients with aMCI (mean age = 65.11 years, SD age = 4.5 
years) and 18 male patients with AD (mean age = 72.2 years, SD age = 9.7 years). A 
standardized eight-point scale was used to indicate educational level (1=primary 
school, 8=university). Written informed consent was obtained from all participants 
and from the primary caregiver of the AD patients. The study was approved by the 
local Medical Ethics Committee of the Maastricht University Medical Center. 
Image acquisition and analysis 
MRI scans were acquired with a 3 Tesla Gyroscan NT MRI scanner (Philips, Best, The 
Netherlands). Structural T1 images were acquired in the sagittal plane using an 
MPRAGE sequence (TR=8, TE= 3,7 msec, FA= 9, FOV= 240 X 240, matrix size= 240 x 
240, number of slices= 180; voxel size = 1 x 1 x 1 mm3). For data analysis, we used a 
manual tracing approach. The images were viewed using GIANT (General Image 
Analysis Tools) (Gronenschild et al., 2010), which is a customized software program 
that allows tracing of regions of interest in a tri-planar and a rotatable 3D surface-
rendered view as well as calculation of volumes of interest. The definitions of 
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boundaries and divisions of the hippocampus and parahippocampal gyrus were 
performed according to the criteria described in a previous publication (Burgmans 
et al., 2009). Volumetric measures were obtained of the anterior, middle, and pos-
terior parts of the hippocampus and parahippocampal gyrus (Figure 1). 
 
 
Figure 1.  
Note. Patterns in the top panel show the subdivision of the hippocampus and parahippocampal gyrus 
along the antero-posterior axis. The anterior part included the anterior 35% of the coronal slices (and 
any rounded off number of slices closest to this cutoff), the middle part comprised 35%, and the poste-
rior part included the remaining 30%. The bottom panel shows the coronal sections of the hippocampus 
(red) and parahippocampal gyrus (blue) along the anterior-posterior axis. 
 
A single rater (CEZ), who was blind to the demographic and cognitive characteris-
tics of the participants, traced all structures. Intra-rater reliability was determined 
by the Intraclass Correlation Coefficient (ICC) (Shrout and Fleiss 1979). Ten random-
ly selected brains were measured twice, and these yielded high test-retest reliabil-
ity. The ICC of the total hippocampal volume was 0.97 (95% confidence interval= 
0.91; 0.99), and the ICC of the total parahippocampal volume was 0.95 (95% confi-
dence interval= 0.84; 0.98). To correct for individual differences in unatrophied 
brain, intracranial volumes were measured using an automated method (FSL Brain 
Extraction Tool) developed at the Oxford Centre for Functional MRI of the brain 
(Smith 2002).  
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Statistical analysis 
Statistical analyses were performed using the Statistical Package for the Social 
Sciences (SPSS Inc, Chicago) version 16.0 for Windows. To compare the mean age, 
educational level, and MMSE scores between the 3 groups, ANOVA (General Linear 
Model; GLM) was performed. For the volumetric comparisons between the 3 
groups, ANCOVA (GLM) was used, with volume as dependent variable, group as 
independent variable, and intracranial volume and age as covariates.  
Three main things were tested in the ANCOVA analysis. First, the effect of group 
was calculated to test the overall difference across the three groups. Second, con-
trasts were calculated by pairwise comparisons among means to test the differ-
ences between two groups: i.e. control vs MCI; control vs AD; and aMCI vs AD. 
Third, the hypothesis that group differences are larger in the parahippocampal 
gyrus than in the hippocampus was tested by adding the hippocampus as covariate 
in the ANCOVA analysis with the parahippocampal gyrus as dependent variable. If 
group differences are still significant in this analysis, we can state that the parahip-
pocampal gyrus has added value in discriminating between groups on top of the 
discriminating ability of the hippocampus. For all tests, Pearson’s correlation coeffi-
cient was calculated as a measure of effect size.  
Results  
The 3 groups differed significantly with respect to age (p = 0.001) and MMSE (p = 
0.000), but did not differ with respect to educational level (p > 0.697). The AD 
group was older (mean age 72.2, SD 9.7) than the other two groups. Minimental 
scores differed in the following order: control (mean MMSE score 28.8, range 27-
30) > MCI (mean MMSE score 27.6, range 22-30) > AD (mean MMSE score 21.0, 
range 10-28). 16 of the 18 AD patients were in a mild stage of the disease (mean 
MMSE score 21.0, range 18-28), and two patients in a moderate-severe stage 
(MMSE score 10 and 15). The mean educational level in the control group was 4.2 
(SD 1.4). The mean educational level in the MCI and the AD group was 3.8 (SD 1.8). 
Volumetric comparisons between the 3 groups are summarized in Tables 1 and 
2. Age and intracranial volume were included as covariates to correct for possible 
age and cohort effects. With regard to the main effect of group on the total vol-
umes of the hippocampus and parahippocampal gyrus: differences between the 
three groups were significant in both volumes (parahippocampal gyrus: F (2,46) = 
24.23, p < 0.001, hippocampus: F (2,46) = 12.07, p < 0.001). Volumes were signifi-
cantly different in the following order: healthy > aMCI > AD. ANCOVA analyses 
demonstrated that the parahippocampal gyrus is better in discriminating between 
groups than the hippocampal gyrus. When we added the hippocampus as covariate 
in the ANCOVA analysis with the parahippocampal gyrus as dependent variable, we 
still found robust significant group differences (F (2,45) = 11.07; p < 0.001). In con-
trast, when we added the parahippocampal gyrus as covariate in the ANCOVA anal-
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ysis with the hippocampus as dependent variable, the significant group differences 
disappeared (F (2,45) = 2.42; p = 0.100). This indicates that the parahippocampal 
volume has added value on top of the discriminating ability of the hippocampus. 
Furthermore, pairwise comparisons between the healthy and aMCI groups showed 
a significant difference in the parahippocampal gyrus (12.4%, F (1,29) = 10.46, p = 
0.003) but not in the hippocampus (1.7%, F (1,29) = 0.85, p = 0.362). When we 
compared the control or the aMCI group with the AD group, significant differences 
were found in both structures (Figure 2). 
With respect to differences along the longitudinal axis in the hippocampus and 
parahippocampal gyrus, the repeated-measures GLM showed a significant group by 
structure interaction (p = 0.034) in the left parahippocampal gyrus when we com-
pared controls with AD patients. The group difference was larger in the anterior 
part than in the middle and posterior parts. No other significant differences were 
found between anterior, middle, and posterior parts. Furthermore, repeated-
measures analysis showed no significant differences between both hemispheres 
(i.e., left-right differences). 
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Figure 2. Boxplot of the hippocampal and parahippocampal gyrus volumes in mm3 in controls, MCI and 
AD patients.  
** = significant difference with control group; * = significant difference with MCI group. 
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Table 1. Volumetric comparisons between the three groups 
Volume in mm3 Controls (n=18) aMCI (n=18) AD (n=18)      
 Mean (SD) Mean (SD) Mean (SD) F(2,46) r p 
HCG total  7464 (794) 7334 (111) 5922 (122) 12.0 0.1 0.000 
HCG ant 2959 (375) 2970 (459) 2452 (500) 8.4 0.4 0.001 
HCG middle 2434 (269) 2321 (333) 1915 (394) 10.0 0.5 0.000 
HCG post 2100 (359) 2045 (434) 1592 (383) 7.0 0.4 0.002 
PHG total  4623 (680) 4047 (732) 3014 (588) 24.2 0.7 0.000 
PHG ant 1657 (318) 1389 (326) 954 (303) 16.6 0.6 0.000 
PHG middle 1646 (322) 1482 (421) 1074 (298) 15.6 0.6 0.000 
PHG post 1.335 (202) 1169 (170) 881 (200) 20.3 0.6 0.000 
HCG total L 3773 (344) 3704 (450) 3050 (684) 11.6 0.5 0.000 
HCG ant L 1503 (210) 1500 (187) 1241 (156) 7.4 0.4 0.002 
HCG middle L 1239 (154) 1194 (154)  994 (217) 11.3 0.5 0.000 
HCG post L 1031 (207) 1009 (188) 813 (241) 4.1 0.4 0.023 
HCG total R 3719 (575) 3630 (709) 2872 (620) 9.4 0.4 0.000 
HCG ant R 1455 (276) 1470 (272) 1204 (287) 5.8 0.3 0.005 
HCG middle R 1194 (183) 1123 (216) 920 (198) 11.3 0.4 0.000 
HCG post R 1069 (159) 1036 (231) 747 (214) 6.8 0.4 0.000 
PHG total L 2321 (487) 2111 (374) 1468 (319) 18.3 0.6 0.000 
PHG ant L 843 (212) 705 (203) 436 (184) 11.7 0.6 0.000 
PHG middle L 839 (205) 188 (794) 555 (129) 12.7 0.5 0.000 
PHG post L 637 (142) 611 (106) 476 (123) 8.3 0.5 0.001 
PHG total R 2301 (274) 1936 (429) 1546 (329) 18.9 0.6 0.000 
PHG ant R 802 (162) 683 (208) 518 (177) 8.3 0.5 0.001 
PHG middle R 812 (100) 693 (159) 586 (140) 11.1 0.6 0.000 
PHG post R 687 (130) 558 (122) 441 (115) 15.3 0.6 0.000 
Note. The group differences were calculated with ANCOVA (Univariate General Linear Model); HCG = 
Hippocampus; PHG = Parahippocampal gyrus; ant = anterior; post = posterior; L = left; R = right; SD = 
Standard deviation; r = effect size by Pearson’s correlation coefficient; p = p value; F (2,46) = F-ratio and 
the degrees of freedom; p, r and F represent group difference.  
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Table 2. Volumetric pairwise comparisons 
 Control and aMCI aMCI and AD Control and AD 
Volume in mm3 % F(1,29) r  P % F(1,29) r  p % F(1,29) r  p 
HCG total  1.7 0.8 0.0 0.362 19.2 12.2 0.5 0.002 20.6 22.7 0.6 0.000 
HCG ant -0.3 0.2 0.0 0.628 17.8 9.2 0.5 0.005 17.1 14.4 0.5 0.001 
HCG middle 4.6 3.5 0.1 0.069 17.4 12.5 0.5 0.001 21.3 30.8 0.6 0.000 
HCG post 2.5 0.3 0.0 0.559 22.0 8.3 0.4 0.007 24.1 15.3 0.5 0.001 
PHG total  12.4 10.4 0.3 0.003 25.5 24.5 0.6 0.000 34.8 36.8 0.7 0.000 
PHG ant 16.1 9.4 0.3 0.004 31.3 12.8 0.5 0.001 42.4 25.2 0.7 0.000 
PHG middle 13.2 4.9 0.2 0.033 19.3 17.4 0.5 0.000 34.7 25.2 0.7 0.000 
PHG post 12.4 9.8 0.4 0.004 24.6 21.6 0.6 0.000 34.0 27.2 0.7 0.000 
HCG total L 1,8 1.2 0.0 0.266 17.6 10.9 0.5 0.003 19.1 19.8 0.5 0.000 
HCG ant L 0.19 0.4 0.0 0.499 17.2 8.0 0.4 0.008 17.4 11.6 0.5 0.002 
HCG middle L 3.6 1.4 0.1 0.233 16.7 12.7 0.5 0.001 19.7 19.7 0.5 0.000 
HCG post L 2.1 0.2 0.0 0.654 19.4 5.0 0.4 0.032 21.1 7.6 0.4 0.010 
HCG total R 2.3 0.7 0.0 0.379 20.8 10.0 0.4 0.004 22.7 19.7 0.5 0.000 
HCG ant R -1.0 0.0 0.0 0.844 18.9 7.7 0.4 0.009 17.2 10.4 0.4 0.003 
HCG middle R 5.9 3.7 0.1 0.063 18.0 8.1 0.4 0.008 22.9 24.4 0.5 0.000 
HCG post R 3.08 0.3 0.0 0.580 27.7 8.5 0.4 0.007 30.1 14.1 0.5 0.001 
PHG total L 9.04 3.4 0.2 0.071 30.4 36.9 0.7 0.000 36.7 24.4 0.7 0.000 
PHG ant L 16.3 4.6 0.3 0.039 38.1 10.9 0.5 0.003 48.2 19.9 0.7 0.000 
PHG middle L 17.9 1.1 0.1 0.282 19.3 26.8 0.6 0.000 33.8 17.7 0.6 0.000 
PHG post L 4.08 0.8 0.1 0.368 22.0 15.6 0.5 0.000 25.3 10.4 0.5 0.003 
PHG total R 15.8 18.4 0.4 0.000 20.1 8.0 0.4 0.008 32.8 35.4 0.7 0.000 
PHG ant R 20.4 6.4 0.3 0.016 18.8 4.5 0.4 0.042 35.4 13.9 0.6 0.000 
PHG middle R 14.6 10.2 0.4 0.003 15.4 4.1 0.4 0.050 27.8 21.1 0.7 0.000 
PHG post R 19.02 11.3 0.4 0.002 20.9 7.7 0.4 0.009 35.8 23.7 0.7 0.000 
Note. The groups differences were calculated with ANCOVA (Univariate General Linear Model); HCG = 
Hippocampus; PHG = Parahippocampal gyrus; % = difference between the two groups (V1-V2 x 100/V1); 
r = effect size by Pearson’s correlation coefficient; p = p value; F(df) = for the covariate effect we give the 
F-ratio and the degrees of freedom (df) 
 84 
Discussion 
The main aim of the present study was to compare volume differences in the hip-
pocampus and parahippocampal gyrus between healthy controls, individuals with 
aMCI, and patients with AD. In addition, differences along the longitudinal axis of 
both structures were investigated. Our results suggest that parahippocampal vol-
ume discriminates better than hippocampal volume especially in the early phase of 
AD. No significant differences were found along the longitudinal axis, except for the 
left parahippocampal gyrus in which the anterior parts showed significantly larger 
differences than the posterior parts when controls were compared to AD patients.  
Our finding that parahippocampal volume discriminates better than hippo-
campal volume is in line with the findings of most previous studies on pathological 
aging in which a comparison was made between healthy and MCI groups (Detole-
do-Morrel et al., 2000; Jack et al., 2000; Jauhiainen et al., 2009; Killiany et al., 2002; 
Pennanen et al., 2004; Xu et al., 2000), between MCI and AD groups (Du et al., 
2001; Jauhiainen et al., 2009; Tapiola et al., 2008; Visser et al., 1999; Xu et al., 
2000), or between healthy and AD groups (Detoledo-Morrel et al., 2000; Dickerson 
et al., 2001; Du et al., 2001; Jauhiainen et al., 2009; Killiany et al., 2002; Pennanen 
et al.,2004). There have been, however, also a few studies that found larger group 
differences in the hippocampus (Detoledo-Morrel et al., 1997; Jack et al.,1997; 
Pennanen et al., 2004; Visser et al., 2002). Nevertheless, in these cases a group of 
AD patients was always involved. Thus, in those cases where the hippocampus was 
found to be a better discriminator than the parahippocampal gyrus, the group 
comparisons were always between MCI and AD, or between control and AD, but 
never between control and MCI. This might indicate that the parahippocampal 
gyrus is a better discriminator particularly in the early (preclinical) phase of AD. The 
suggestion that the parahippocampal gyrus in particular is a highly sensitive marker 
with which to detect AD at a very early stage is in line with earlier reports on the 
entorhinal cortex (Detoledo-Morrel et al., 2004; Dickerson et al., 2001; Pennanen 
et al., 2004). The present study adds a new finding as it shows that this is not only 
the case with regard to the anterior part, but also with regard to the posterior part 
of the parahippocampal gyrus. 
The present data are also partly in line with a previous study by our group 
(Burgmans et al., 2009) in which healthy, aging individuals with and without 
memory decline were compared. In that study we also reported larger group dif-
ferences in the parahippocampal gyrus. However, we found the largest group dif-
ference in the posterior part of the parahippocampal gyrus. This is in contrast with 
the present results, since here we found larger differences in the anterior part of 
the left parahippocampal gyrus than in the posterior parts of the left parahippo-
campal gyrus between controls and AD patients. A possible explanation for these 
different findings could be that atrophy in the posterior medial temporal lobe is 
more strongly related to healthy aging, whereas atrophy in the anterior medial 
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temporal lobe is more strongly related to pathological aging. In a recent study, Raji 
et al., (2009) observed that in normal aging the most affected region was the pos-
terior part of the hippocampus, while in AD patients the most affected regions 
were the anterior parts of the hippocampus and the parahippocampal gyrus.  
There remain a few methodological issues to be addressed. First, our MRI data 
were acquired at only one time point, which precludes the assessment of actual 
pathological aging changes in volume, or of causality. Second, we included only 
male participants in order to decrease interindividual variation. We must therefore 
be cautious with generalizing our findings to females. Previous studies, however, 
did not reveal substantial gender-related differences with respect to hippocampal 
and parahippocampal atrophy in AD. Third, the subdivision applied to the hippo-
campus and the parahippocampal gyrus was an MRI macroscopical one. We chose 
to divide both structures into three subregions along the longitudinal axis, because 
the literature suggests there are important differences in age-related and patholog-
ical-related changes between the anterior and posterior areas. However, there are 
no clear anatomical reasons for the cutoff points used in the present study (i.e., 
35% for the anterior volume; 35% for the middle volume; and 30% for the posterior 
volume). Nevertheless, one of the aims of this study was to explore group differ-
ences along the longitudinal axis, which has been made possible by our MRI-based 
approach. When it comes to investigating the subregions of the medial temporal 
lobe in more detail, cytoarchitectonic studies are considered more ideal.  
In sum, our results suggest that parahippocampal volume discriminates better 
than hippocampal volume between cases of healthy aging, aMCI, and AD, in partic-
ular in the early phase of the disease. Our findings stress the importance of para-
hippocampal atrophy as an early biomarker of AD. Such predictive biological mark-
ers could be of great help for the development of early interventions designed to 
retard the progression of the disease. A possible implication could be a visual rating 
scale of the parahippocampal gyrus, similar to the one that exists for the hippo-
campus (Scheltens et al., 1992), which could help detect the earliest neurodegen-
erative changes indicative of AD in routine clinical practice. 
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CHAPTER 7 
Concluding remarks 
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In this thesis, the dementia syndrome is described from a multidimensional per-
spective, including clinical, neuropathological, and neuroimaging features of de-
mentia. The main aim of the research underlying it was to investigate the correla-
tion between clinical and neuropathological features of dementia. The specific 
research questions are therefore related to the correlations between clinical and 
neuropathological diagnoses and to clinical features of the dementia syndrome. 
Most of the research reported in this thesis was based on brain tissue from the 
Brain Bank of Navarre (Pamplona, Spain) and the Netherlands Brain Bank (Amster-
dam). All the participants included in the study of the correlations between clinical 
and neuropathological diagnoses had been diagnosed with a neurodegenerative 
disorder (most of them with dementia) during life as well as post-mortem. All types 
of dementia present were included in order to assess the correlation between 
ante-mortem and post-mortem diagnoses. Clinical features, such as the prevalenc-
es of risk factors and neuropsychiatric symptoms (NPSs), were studied in patients 
with Alzheimer´s disease (AD) and vascular dementia (VaD), which are the most 
common types of dementia.  
Summary of the main findings 
Multiple pathologies in dementia  
Chapter 2 discusses the rate of agreement between clinical and neuropathological 
diagnoses of dementia. The data showed low rates of agreement for the most 
common diagnoses, which is mainly due to the fact that several pathological 
changes often co-occur in the brains of demented patients. Overall, the agreement 
between clinical and pathological diagnosis was less than half (44%), confirming 
that the underlying biological findings often differ from the neuropathological dis-
ease suggested by the clinical diagnosis. Along the same line, Chapter 3 focuses on 
the relationship between the most prevalent pathological changes co-occurring in 
the same brain, which are Alzheimer´s disease (AD)-related, Lewy body (LB)-
related, and vascular pathology (VaD or cerebrovascular lesions (CVL)). The analysis 
found evidence to support a positive association between AD and vascular lesion 
severity, suggesting that there may be a common pathogenesis underlying AD and 
vascular lesions. On the other hand, the results did not support a link between AD 
and LB pathologies, though it appears that LB pathology is a mediating factor which 
leads to a positive relationship between the severity of CVLs and AD-related pa-
thology. 
Cerebrovascular risk factors in dementia 
The study reported on in Chapter 4 explored the role of vascular risk factors in 
dementia by estimating the prevalence of different risk factors in cases of dementia 
with neuropathologically confirmed AD, VaD and mixed AD plus vascular pathology. 
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Previous in vivo studies have reported various vascular conditions to be risk factors 
for dementia, and differences in risk factor profile have been found between sub-
types of dementia. In order to compare the results of the sample from the Nether-
lands Brain Bank (NBB) with a more representative sample of the Dutch population, 
data from several control groups representing the elderly Dutch population were 
also included. Comparison of the three disease groups did not reveal significant 
differences in the prevalence of any of the vascular risk factors considered, except 
for a greater prevalence of a history of stroke in VaD and MD. Compared to con-
trols, the only differences found were that smoking was more common in AD cases 
and that more VaD cases had a history of stroke. Our data show that the use of 
neuropathological confirmation of dementia diagnoses led to the disappearance of 
most of the previously reported differences in vascular risk factors between AD, 
MD, VaD, and controls. 
Neuropsychiatry in vascular and degenerative pathology 
Chapter 5 discusses the presence of NPSs associated with dementia in patients with 
neuropathologically confirmed AD and VaD. The most common symptom in the 
sample as a whole was agitation (45 cases, 57%), followed by depression (33, 
41.2%) and anxiety (28, 35.4%). No significant differences between groups were 
found regarding the prevalences of NPSs, suggesting that NPSs are related to de-
mentia in a non-specific way, that is, AD and VaD patients do not differ significantly 
in terms of NPSs. Our results suggest that the prevalence of these NPSs cannot be 
related to the dementia diagnosis of AD or VaD. We want to stress that previous 
studies were based on clinical diagnoses, which were probably often not sufficient-
ly accurate, especially those for VaD. Our study is the first one in the literature to 
provide an assessment of NPSs in types of dementia based on clinical as well as 
neuropathological diagnoses.  
Early stages of dementia  
Chapter 6 discusses magnetic resonance imaging (MRI) markers of early stage AD. 
Previous neuropathological studies have identified the parahippocampal gyrus as 
the first structure to be involved in AD (Braak & Braak, 1991), but neuroimaging 
studies have been focusing on changes in the hippocampus as a biomarker for early 
stage AD. The role of changes in the parahippocampal gyrus as a neuroimaging 
biomarker for early stage AD was explored by measuring the volume of this struc-
ture and of the hippocampus in healthy volunteers, and in patients with amnestic 
mild cognitive impairment (aMCI) and mild AD. The results suggest that parahippo-
campal volume is better able to discriminate between cases of healthy ageing, 
aMCI, and mild AD than hippocampal volume, especially in the early stages of the 
disease. These findings underline the importance of parahippocampal atrophy as 
an early biomarker of AD, which had not been demonstrated before.  
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Methodological considerations 
There are some methodological issues that need to be addressed as regards the 
research underlying this thesis, mainly arising from the characteristic limitations of 
a retrospective neuropathological study not based on a population series but on a 
series of donors from brain banks. 
First, as is inherent in all clinicopathological studies, the data used for our the-
sis are subject to selection bias. Such selection bias most commonly results from 
referral bias, which is influenced by the severity of the disorder and the manage-
ment provided by the caregiver or caregivers of the demented person (Zaccai et al., 
2006). In fact, patients with rarer neuropathological conditions are more likely to 
become brain bank donors (Jicha et al., 2008; Schneider et al., 2009). For instance, 
there is a particularly high prevalence of FTLD and prion disease cases in the sam-
ple from the Brain Bank of Navarre. Besides, donors to brain banks are usually el-
derly patients in the later stages of their diseases. Since our samples from the brain 
banks are thus not entirely representative of the European population, our findings 
may have been affected by selection bias, so they must be interpreted very cau-
tiously, especially when it comes to assessing demographical or epidemiological 
variables.  
Second, the relatively small number of participants in our clinico-neuro-
pathological studies could have resulted in low statistical power and, hence, failure 
to find significant results. Furthermore, most of the donors to the brain banks were 
in the later stages of their diseases; for instance, most individuals with AD were at 
Braak stages of V or VI. This narrow range of Braak stages may have hampered the 
process of finding robust correlations, especially when studying the relationship 
between the severity of AD pathology and CVLs. These results have to be interpret-
ed by taking into account that they apply mostly to the later stages of the dementia 
syndrome. We have no neuropathological findings for the early stages of the dis-
ease, and consequently have no information about the way pathology spreads 
through the brain until its later stages.  
Third, there was a time lag between clinical assessment and pathological data 
collection in our studies. In addition, clinical data were not collected prospectively, 
but in a retrospective way from patients’ medical and brain bank records. Although 
clinical studies can be strictly controlled and prospective, clinical information is 
often lacking at the moment of neuropathological analysis. The research for this 
thesis found that clinical parameters, such as the presence of vascular risk factors 
or NPSs, were not always available or had not been compiled consistently. Indeed, 
no standardized tools were used for assessing the presence and severity of NPSs. 
On the other hand, the availability of a neuropathological diagnosis is a considera-
ble advantage. In a clinico-pathological study like ours, pure AD and VaD cases can 
be distinguished. Only 40 pure VaD cases were diagnosed in the NBB sample, while 
660 pure AD cases were diagnosed in the same period of time. As mentioned 
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above, there was a high degree of heterogeneity in terms of the vascular lesions in 
the group. Accordingly, with pure VaD being such a rare diagnosis in the available 
sample, it was impossible to establish more homogeneous vascular subgroups that 
were large enough for robust statistical analyses. Therefore, the conclusions apply 
to the heterogeneous group which is referred to as VaD, but which is not a pure 
nosological entity. Note that this approach is similar to that adopted in previous 
studies (Kalaria et al., 2004; Pantoni et al., 2006; Alafuzoffa et al., 2012 ). 
Implications 
What do our findings mean for diagnosis, for doctors who look after people with 
this syndrome, for pathologists, for researchers, and for patients? This thesis raises 
several important questions, and an attempt will be made to answer these ques-
tions, approaching them from different perspectives, i.e. from both a clinical and a 
neuropathological point of view, as well as from the perspective of researchers, 
brain banks, and of course patients and their caregivers.  
Nosological implications: multiple pathologies in dementia 
The criteria for differentiating between dementia types are currently based on 
neuropathological changes, and follow traditional nosological classifications. How-
ever, it is known that clinical diagnoses often need to be revised when neuropatho-
logical findings are taken into account (Braak & Braak, 1991; Kovacs et al., 2008; 
Brunnstrom & Englund, 2009; Echávarri et al., 2012; Alzheimer´s Association, 2012), 
since the high incidence of comorbid neuropathologies complicates the differentia-
tion between dementia diagnoses in clinical practice. The findings presented in the 
present thesis show that the co-occurrence of neuropathological changes is likely 
to increase with advanced age, as the incidence of comorbidity was higher in pa-
tients over the age of 80. This is in line with other results for community-dwelling 
older persons and autopsy series (Galasko et al., 1994; Echávarri et al., 2011). This 
thesis supports the idea of a multidimensional approach to diagnosing dementia, in 
which dementia syndromes are not categorized into diagnostic types, but are seen 
as one clinical syndrome representing the gradual accumulation of multiple pathol-
ogies. This multidimensional approach takes into consideration that categorical 
diagnoses made in vivo often do not correspond to the multimorbid pathology, and 
may thus be oversimplified. In agreement with Richard and Brayne (Richards & 
Brayne, 2009), we claim that diagnostic classifications made on the basis of as-
sumed clinicopathological correlations should be changed so as to arrive at a global 
approach. Thus, this thesis underlines that a multidimensional approach would not 
only increase the accuracy of dementia diagnoses, but also lead to a better under-
standing of neurodegenerative diseases among clinicians.  
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Cerebrovascular risk factors in dementia 
Previous studies of the relationship between vascular risk factors and dementia 
have produced inconsistent results. Although data from longitudinal epidemiologi-
cal studies have supported the view that there is a relationship between vascular 
risk factors and dementia (Pohjasvaara et al., 1998; Knopman et al., 2001; Kivipelto 
et al., 2001; Kivipelto et al., 2005; Kuller et al., 2005; Reitz et al., 2008; Schneider et 
al., 2009; Knopman & Roberts, 2010), this was not confirmed by some other re-
searchers (Launer et al., 2008; Purnell et al., 2009; Richard et al., 2009). In agree-
ment with other studies, this thesis notes that common clinical dementia (like AD, 
Lewy bodies dementia or VaD) cases are often in fact mixed conditions, with Alz-
heimer’s, vascular and Lewy body-related pathologies (Dickerson et al., 2001; 
Jellinger & Attems, 2003; Trojanowski et al., 2003; Parkkinen et al., 2008; Knopman 
& Roberts, 2010; Echávarri et al., 2012). This would explain the failure to identify 
vascular risk factor patterns associated with types of dementia (AD, VaD, or MD). In 
Chapter 4, we argued that vascular risk factors may indeed not be related to the 
presence of dementia, except for stroke history in VaD. Specifically, no differences 
were found regarding the distribution of vascular risk factors in AD, VaD, and mixed 
dementia, suggesting that the burdens caused by vascular and AD type lesions are 
independent of each other. On the other hand, Chapter 3 presents evidence indi-
cating a relationship between degenerative and vascular lesion severity, which is 
consistent with a synergic effect of the two types of lesions in dementia (Launer et 
al., 2000). From a clinical perspective, bearing in mind all the aforementioned find-
ings, this thesis suggests that the presence of vascular risk factors should be taken 
into account in demented patients. That is, it is essential to consider the vascular 
component of degenerative dementias to provide better treatment options for 
demented patients; the data reflect how important it is to prevent vascular risk 
factors throughout the course of dementia, in order to minimize the severity of the 
disease.  
Neuropsychiatry in vascular and degenerative pathology 
In agreement with prior studies, our study of the NBB sample suggests that pure 
VaD cases are rather rare, making it difficult to attribute different patterns of symp-
toms associated with dementia specifically to AD or VaD (Launer et al., 2008). Our 
results suggest that the prevalence of these NPSs cannot be related to the underly-
ing (and pathologically verified) dementia diagnosis of AD or VaD, which means 
that NPSs in dementia do not differ with the subtype of dementia. A few previous 
studies have compared NPSs between dementia subtypes, with conflicting results. 
Some studies found higher prevalences of NPSs in VaD, including depression, anxie-
ty, or agitation, while others found higher prevalences in AD, including anxiety and 
agitation, and still others found no differences between groups (Ballard et al., 2000; 
Caputo et al., 2008; Johnson et al., 2011). Again, these contradictory results may be 
due to a lack of accuracy in diagnosing dementia subtypes. Our study is the only 
one performed on this topic which provides a sample with neuropathological con-
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firmation of clinical diagnoses. Although no differences regarding NPSs were found 
between the AD and VaD groups, we stress the high prevalence of NPSs in dement-
ed patients. Thus, it is important to investigate these NPSs in each demented pa-
tient individually, to be able to improve the therapeutic approach and decrease 
caregiver burden as much as possible. 
Early stage dementia 
Results presented in this thesis suggest that changes in the parahippocampal gyrus 
are a highly sensitive marker for detecting AD at a very early stage. This is in line 
with earlier reports on the anterior part of the parahippocampal gyrus, the ento-
rhinal cortex (Reitz et al., 2008; Echávarri et al., 2011). The present thesis adds to 
the existing body of knowledge in that it shows that this is also true for the posteri-
or part of the parahippocampal gyrus. The findings underline the importance of 
parahippocampal atrophy as an early biomarker of AD, which has never been 
shown before. In fact, there have been no previous studies focusing on the role of 
the parahippocampal gyrus as a neuroradiological biomarker of AD. Such predictive 
biological markers could be very valuable for the development of early interven-
tions designed to delay the progression of the disease. An implication is that it 
might be useful to develop a visual rating scale of the parahippocampal gyrus, simi-
lar to the one that exists for the hippocampus (Scheltens et al., 1992), as this could 
help detect the earliest neurodegenerative changes indicative of AD in routine 
clinical practice. 
Directions for the future 
The high dependency associated with dementia results in very high costs to society 
(Alzheimer´s Association, 2012), which makes research into the aetiology and path-
ogenesis of late-life dementia a high priority. Beyond the pathological confirmation 
of diagnoses, working with neuropathological findings allows a range of other is-
sues to be investigated. These include identification of the brain lesions that best 
correlate with cognitive decline, and the assessment of links between pathological 
findings and potential risk factors. This thesis highlights the role of brain banks in 
research in neurosciences, in particular in dementia; the study of brain tissue is 
essential since it provides useful feedback to clinical teams and may also lead to 
further improvements in the diagnostic procedures (Brunnstrom & Englund, 2009). 
Further systematic comparisons of clinical and pathological dementia diagnoses are 
needed.  
 The potential to establish an early diagnosis, to predict the underlying 
pathology during life, and to stage disease progression will all be required for trials 
of disease-specific treatments in the future. This approach highlights the im-
portance of brain lesions as substrates for the decline noted in normal ageing, in 
comparison to dementia. It is possible to test hypothetical semi-quantitative 
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thresholds definable in terms of a staging system to classify clinical dementia and 
shed light on the critical steps in the neurobiological progression of cognitive de-
cline through states such as MCI. Thus, identifying neuropathological markers rele-
vant to cognitive function is useful for both the diagnostic process and our under-
standing of the molecular and clinical aetiologies of various types of dementia, and 
can ultimately be expected to result in the development of better treatments.  
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Dementia is a clinical syndrome characterized by an acquired and persistent im-
pairment in multiple cognitive domains that is severe enough to interfere with 
everyday functioning. Although standardized clinical and neuropathological criteria 
for different subtypes of dementia have been proposed in consensus meetings, 
correlations between clinical and neuropathological symptoms and diagnoses are 
far from optimal. The research reported on in this thesis investigated this relation-
ship between the clinical and neuropathological approaches to dementia. The gen-
eral introduction (Chapter 1) provides background information regarding clinical 
and neuropathological characteristics of dementia subtypes, and outlines the main 
aim and research questions of this thesis.  
In Chapter 2 we investigate the level of agreement between clinical and neu-
ropathological diagnoses in neurodegenerative disorders. We found a mean 
agreement of 44.0% between the clinical diagnosis and the purely neuropathologi-
cal diagnosis. This level of agreement differed between dementia subtypes, e.g. 
85% for prion disease, 49% for AD and 0% for Lewy bodies dementia. Our data 
confirmed that co-occurrence of multiple neuropathological disorders is very com-
mon in individuals with dementia, supporting a multidimensional approach to di-
agnosing dementia, in which dementia syndromes are characterized using a combi-
nation of various neuropathological dimensions.  
Chapter 3 discusses the associations between the severity of Alzheimer pa-
thology (i.e., Braak stage), cerebrovascular lesions (CVLs) and Lewy bodies in de-
mented patients. Cases of pure AD and AD with comorbidity were analyzed togeth-
er and also separately, in both groups. For the group as a whole, we found a signifi-
cant positive relationship between AD Braak stage and CVL severity, which was not 
found when analyzing pure AD and AD plus comorbidity groups separately. No 
relationship was found between Braak and LB stages. Our study supports a positive 
association between AD pathology and CVLs in demented patients with AD, sug-
gesting that AD and CVLs may have a common pathogenesis.  
Chapter 4 compares the prevalences of vascular risk factors in neuropathologi-
cally confirmed cases of AD, vascular dementia (VaD), and mixed AD and VaD (MD). 
It compares the results with published prevalence data for elderly local Dutch con-
trol populations. Comparing the three disease groups did not reveal significant 
differences in prevalence for any of the risk factors considered, except for a greater 
prevalence of a history of stroke in VaD and MD. Compared to controls, the only 
differences found were that smoking was more common in AD cases and more VaD 
cases had a history of stroke. We argue that risk factors may not be related to the 
presence of dementia, except for stroke history in VaD. Although differences in 
vascular risk factors between AD, MD, and VaD had previously been reported from 
in vivo studies, we demonstrate that these differences disappear when using neu-
ropathological confirmation of dementia diagnoses.  
Chapter 5 discusses the prevalence of NPSs associated with dementia in cases 
with neuropathologically confirmed AD and VaD. Our study failed to find differ-
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ences between groups regarding these symptoms, suggesting that AD and VaD 
patients do not differ significantly in terms of NPSs. This is the first study on this 
topic to use neuropathological confirmation of the diagnoses.  
Chapter 6 examines the role of the parahippocampal gyrus as an early neu-
roimaging biomarker of AD by measuring the volume of this structure and the hip-
pocampus in healthy participants and participants with amnestic mild cognitive 
impairment (aMCI) and mild AD. Our results suggest that parahippocampal volume 
discriminates better than hippocampal volume between cases of healthy ageing, 
aMCI, and mild AD, especially in the early stages of the disease. Our study is this 
first one to demonstrate the importance of parahippocampal atrophy as the earli-
est neuroradiological biomarker of AD. 
Chapter 7 presents some concluding remarks and summarizes the main find-
ings of this thesis, comparing them with those previously reported in the literature. 
It also presents some methodological considerations and discusses implications of 
our results in relation to clinical practice and further research.  
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nes. ¡Ojalá sea capaz de seguir viviendo así! 
 
MUCHAS GRACIAS A TODOS 
 
 
 
 
 
 
 
 107
 
CURRICULUM VITAE 
Carmen Echávarri Zalba was born 17 April 1976 in Pamplona, Spain. She studied 
medicine at the University of Navarra, Spain (1994-2000), continuing her training in 
neurology at the Hospital of Navarra in Pamplona, Spain (2002-2006). She has 
worked as a general neurologist and as a neurologist specializing in psychogeriatry 
and dementia in various places: the Department of Neurology at the Hospital of 
Navarre, the Psychogeriatric Clinic Josefina Arregui in Alsasua (Navarra), the 
Memory Clinic at the ACE foundation in Barcelona (Spain), and at the hospitals of 
Harrogate and Scarborough (United Kingdom). She completed a three-year training 
period in neuropsychology (organized by the Spanish Society of Neurology in Barce-
lona). She further developed her skills in neuropathology and brain bank manage-
ment at various hospitals: the Department of  Pathology of the Complex of Hospi-
tals of Navarra under Drs Teresa Tuñón and Federico García-Bragado, the Depart-
ment of Neuropathology at the University Hospital of Belltvitge (Barcelona, Spain) 
under Professor Isidro Ferrer, the Department of Neuropathology and Brain Bank 
of Cambridge at Addenbrooke´s Hospital (United Kingdom) under Dr John Xuereb 
and the Department of Neuropathology and Brain Bank of the Netherlands (at the 
VU Medical Center) under Professor Annemieke Rozemuller and Dr Wouter Kam-
phorst.  
She completed her doctorate courses in neurosciences at the University Clinic of 
Navarre (2003-3006) under Professor Jose Masdeu, and started her PhD project at 
the Department of Neuropsychiatry and Psychology at Maastricht University under 
the supervision of Professor Frans Verhey, Professor Harry Uylings and Dr Saartje 
Burgmans.  
 
 
 
 
 108 
PUBLICATIONS 
Erro, M.E., Echávarri, C., Tuñón, T.; 2006. Síndrome de la cabeza caída secundario a 
miopatía nemalínica  [Dropped head syndrome secondary to nemalinic myopathy]. 
Revista  de Neurología 21 (7), 376-7 (in Spanish).  
 
Iriarte, J., Ayuso, T., Echávarri, C., Alegre, M., Urrestarazu, E., Lacruz, F.,  Gállego, J., 
Artieda, J.; 2007. Agrypnia excitata in fatal familial insomnia. A video-polygraphic 
study. Neurology 69(6), 607-8. 
 
Echávarri, C., Erro, M.E; 2007. Trastornos del sueño en los ancianos y en demencias  
[Sleep disorders in the elderly and in dementias]. An Sist Sanit Navar. 30 Suppl 1, 
155-61 (in Spanish). 
 
Cabada, T., Caballero, M.C., Echávarri, C., Solchaga, S., Bacaicoa, M.C.; 2009. Puesta 
al día en radiopatología en demencias: resonancia magnética postmortem [Radio-
pathologic update on dementias: postmortem magnetic resonante]. Radiología 
51(2), 127-39 (in Spanish). 
 
Echávarri, C., Cabada, T., Caballero, C.; 2010. Correlato patológico de leucoaraiosis 
en estudios de resonancia magnética postmortem en enfermedad de Alzheimer y 
otras demencias [Pathological correlate of leukoaraiosis in postmortem MRI studies 
in Alzheimer  disease and other dementias. Alzheimer]. Real Invest Demenc 44, 15-
23 (in Spanish). 
 
Echávarri, C., Aalten, P., Uylings, H.B.M., Jacobs, H.I.L., Visser, P.J., Gronenschild, 
E.H.B.M., Verhey, F.R.J., Burgmans, S; 2011. Atrophy in the parahippocampal gyrus 
as an early biomarker of Alzheimer’s disease. Brain Struct Funct 215, 265–271. 
 
Echávarri, C., Caballero, M.C., Aramendía, A., García-Bragado, F.,Tuñón, T; 2011. 
Multi-protein deposits in neurodegenerative disorders. Our experience in the Tis-
sue Brain Bank of Navarra. The Anatomical Record 294, 1191–1197.  
 
Echávarri, C., Burgmans, S., Caballero, M.C., García-Bragado, F., Verhey, F.R.J., 
Uylings, H.B.M; 2012. Co-occurrence of different pathologies in dementia: implica-
tions for dementia diagnosis. Journal of Alzheimer´s Disease 30(4), 909-917.    
 
Echávarri, C., Burgmans, S., Uylings, H.B.M., Kamphorst, W., Cuesta, M.J., Peralta, 
V., Rozemuller, A.J.M., Verhey, F.R.J; 2012. Neuropsychiatric symptoms in Alz-
heimer´s disease and vascular dementia. Journal of Alzheimer´s Disease 33 (3). 
 
 109
SUBMITTED 
Echávarri, C., Burgmans, S.,Tuñón, T., Jáuregui, I., Verhey, F.R.J., Uylings, H.B.M., in 
revision. Correlation between Braak stage and comorbidity in Alzheimer’s disease. 
Neurobiology of Aging. 
 
Echávarri, C., Burgmans, B., Verhey, F.R.J., Uylings, H.B.M., Layana, E., Rozemuller, 
A.J.M., Kamphorst, W., in revision. Vascular risk factors in neuropathologically con-
firmed Alzheimer's disease and vascular dementia. Journal of Alzheimer´s Disease.  
 
Basterra, V., Adán, J., Echávarri, C., Sánchez, A.M., Peralta, V., Manuel J. Cuesta, 
M.J., in revision. Frontotemporal dementia and myotonic dystrophy type 1. A case 
report. The Neurologist.  
 
Echávarri, C., Cabada, T., Caballero, M.C., Aramendia, A., Garcia-Bragado, F., 
Tuñón, T., in revision. Hippocampal volume and signal intensity in post-mortem 
magnetic resonance imaging in dementia. The Anatomical Records. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
